Publications

  1. Necela BM, Axenfeld BC, Serie DJ, Kachergus JM, Perez EA, Thompson EA, Norton N. The antineoplastic drug, trastuzumab, dysregulates metabolism in iPSC-derived cardiomyocytes. Clin Transl Med. 2017 Dec; 6 (1):5 Epub 2017 Jan 18
    View PubMed
  2. Cortes J, Rugo HS, Awada A, Twelves C, Perez EA, Im SA, Gomez-Pardo P, Schwartzberg LS, Dieras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, O'Shaughnessy J. Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial. Breast Cancer Res Treat. 2017 Nov; 166 (1):327-328
    View PubMed
  3. Andersson M, Lopez-Vega JM, Petit T, Zamagni C, Easton V, Kamber J, Restuccia E, Perez EA. Efficacy and Safety of Pertuzumab and Trastuzumab Administered in a Single Infusion Bag, Followed by Vinorelbine: VELVET Cohort 2 Final Results. Oncologist. 2017 Oct; 22 (10):1160-1168 Epub 2017 June 07
    View PubMed
  4. Serie DJ, Crook JE, Necela BM, Dockter TJ, Wang X, Asmann YW, Fairweather D, Bruno KA, Colon-Otero G, Perez EA, Thompson EA, Norton N. Genome-wide association study of cardiotoxicity in the NCCTG N9831 (Alliance) adjuvant trastuzumab trial. Pharmacogenet Genomics. 2017 Oct; 27 (10):378-385
    View PubMed
  5. Cortes J, Rugo HS, Awada A, Twelves C, Perez EA, Im SA, Gomez-Pardo P, Schwartzberg LS, Dieras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, O'Shaughnessy J. Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial. Breast Cancer Res Treat. 2017 Sep; 165 (2):329-341 Epub 2017 June 13
    View PubMed
  6. Reinholz MM, Chen B, Dueck AC, Tenner K, Ballman K, Riehle D, Jenkins RB, Geiger XJ, McCullough AE, Perez EA. IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2+ Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831. Clin Cancer Res. 2017 Aug 01; 23 (15):4203-4211 Epub 2017 May 22
    View PubMed
  7. Twelves C, Cortes J, O'Shaughnessy J, Awada A, Perez EA, Im SA, Gomez-Pardo P, Schwartzberg LS, Dieras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, Rugo HS. Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial. Eur J Cancer. 2017 May; 76:205-215.
    View PubMed
  8. Perez EA, Ballman KV, Mashadi-Hossein A, Tenner KS, Kachergus JM, Norton N, Necela BM, Carr JM, Ferree S, Perou CM, Baehner F, Cheang MC, Thompson EA. Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breaty st Tumors from the NCCTG (Alliance) N9831 Trial. J Natl Cancer Inst. 2017 Feb; 109 (2) Epub 2016 Oct 28
    View PubMed
  9. Perez EA, Ballman KV, Mashadi-Hossein A, Tenner KS, Kachergus JM, Norton N, Necela BM, Carr JM, Ferree S, Perou CM, Baehner F, Cheang MC, Thompson EA. Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breast Tumors from the NCCTG (Alliance) N9831 Trial. J Natl Cancer Inst. 2017 Feb 01; 109: (2)1-8.
    View PubMed
  10. Perez EA, Barrios C, Eiermann W, Toi M, Im YH, Conte P, Martin M, Pienkowski T, Pivot X, Burris H 3rd, Petersen JA, Stanzel S, Strasak A, Patre M, Ellis P. Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study. J Clin Oncol. 2017 Jan 10; 35 (2):141-148 Epub 2016 Nov 07
    View PubMed
  11. Shah MV, Wiktor AE, Meyer RG, Tenner KS, Ballman KV, Green SJ, Sukov WR, Ketterling RP, Perez EA, Jenkins RB. Change in Pattern of HER2 Fluorescent in Situ Hybridization (FISH) Results in Breast Cancers Submitted for FISH Testing: Experience of a Reference Laboratory Using US Food and Drug Administration Criteria and American Society of Clinical Oncology and College of American Pathologists Guidelines. J Clin Oncol. 2016 Oct 10; 34 (29):3502-3510
    View PubMed
  12. Sonnenblick A, de Azambuja E, Agbor-Tarh D, Bradbury I, Campbell C, Huang Y, Dueck AC, Pritchard KI, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Gomez H, Perez EA, Piccart M, Azim HA Jr. Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial. J Natl Cancer Inst. 2016 Aug; 108: (8).
    View PubMed
  13. Nahleh ZA, Barlow WE, Hayes DF, Schott AF, Gralow JR, Sikov WM, Perez EA, Chennuru S, Mirshahidi HR, Corso SW, Lew DL, Pusztai L, Livingston RB, Hortobagyi GN. SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. Breast Cancer Res Treat. 2016 Aug; 158: (3)485-95.
    View PubMed
  14. Knutson KL, Clynes R, Shreeder B, Yeramian P, Kemp KP, Ballman K, Tenner KS, Erskine CL, Norton N, Northfelt D, Tan W, Calfa C, Pegram M, Mittendorf EA, Perez EA. Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain. Cancer Res. 2016 Jul 01; 76 (13):3702-10 Epub 2016 Apr 20
    View PubMed
  15. Krop IE, Mayer IA, Ganju V, Dickler M, Johnston S, Morales S, Yardley DA, Melichar B, Forero-Torres A, Lee SC, de Boer R, Petrakova K, Vallentin S, Perez EA, Piccart M, Ellis M, Winer E, Gendreau S, Derynck M, Lackner M, Levy G, Qiu J, He J, Schmid P. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016 Jun; 17: (6)811-821.
    View PubMed
  16. Piccart-Gebhart M, Holmes E, Baselga J, de Azambuja E, Dueck AC, Viale G, Zujewski JA, Goldhirsch A, Armour A, Pritchard KI, McCullough AE, Dolci S, McFadden E, Holmes AP, Tonghua L, Eidtmann H, Dinh P, Di Cosimo S, Harbeck N, Tjulandin S, Im YH, Huang CS, Dieras V, Hillman DW, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Gomez H, Suter T, Gelber RD, Perez EA. Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib andor Trastuzumab Treatment Optimization Trial. J Clin Oncol. 2016 Apr 01; 34: (10)1034-42.
    View PubMed
  17. Tan WW, Allred JB, Moreno-Aspitia A, Northfelt DW, Ingle JN, Goetz MP, Perez EA. Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients. Clin Breast Cancer. 2016 Apr; 16 (2):82-6 Epub 2015 Nov 17
    View PubMed
  18. Majithia N, Atherton PJ, Lafky JM, Wagner-Johnston N, Olson J, Dakhil SR, Perez EA, Loprinzi CL, Hines SL. Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up. Support Care Cancer. 2016 Mar; 24: (3)1219-26.
    View PubMed
  19. Advani PP, Ballman KV, Dockter TJ, Colon-Otero G, Perez EA. Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial. J Clin Oncol. 2016 Feb 20; 34: (6)581-7.
    View PubMed
  20. Crozier JA, Advani PP, LaPlant B, Hobday T, Jaslowski AJ, Moreno-Aspitia A, Perez EA. N0436 (Alliance): A Phase II Trial of Irinotecan With Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline andor Taxane-Containing Therapy. Clin Breast Cancer. 2016 Feb; 16: (1)23-30.
    View PubMed
  21. Perez EA, Ballman KV, Tenner KS, Thompson EA, Badve SS, Bailey H, Baehner FL. Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer. JAMA Oncol. 2016 Jan; 2 (1):56-64
    View PubMed
  22. Perez EA. Treatment strategies for advanced hormone receptor-positive and human epidermal growth factor 2-negative breast cancer: the role of treatment order. Drug Resist Updat. 2016 Jan; 24:13-22.
    View PubMed
  23. Norton N, Advani PP, Serie DJ, Geiger XJ, Necela BM, Axenfeld BC, Kachergus JM, Feathers RW, Carr JM, Crook JE, Moreno-Aspitia A, Anastasiadis PZ, Perez EA, Thompson EA. Assessment of Tumor Heterogeneity, as Evidenced by Gene Expression Profiles, Pathway Activation, and Gene Copy Number, in Patients with Multifocal Invasive Lobular Breast Tumors. PLoS One. 2016; 11: (4)e0153411.
    View PubMed
  24. Cortes J, Rugo HS, Twelves C, Awada A, Perez EA, Im SA, Zhao C, Hoch U, Tomkinson D, Buchanan J, Tagliaferri M, Hannah A, O'Shaughnessy J. Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial. Springerplus. 2016; 5: (1)1033.
    View PubMed
  25. Crozier JA, Cornell LF, Rawal B, Perez EA. Breast cancer brain metastases: Molecular subtype, treatment and survival. Breast Dis. 2016; 36: (4)133-141.
    View PubMed
  26. Shah MV, Wiktor AE, Meyer RG, Tenner KS, Ballman KV, Green SJ, Sukov WR, Ketterling RP, Perez EA, Jenkins RB. Change in pattern of HER2 fluorescent in situ hybridization (FISH) results in breast cancers submitted for FISH testing: Experience of a reference laboratory using US Food and Drug Administration criteria and American Society of Clinical Oncology and College of American Pathologists guidelines Journal of Clinical Oncology. 2016; 34: (29)3502-10.
  27. Liu MC, Pitcher BN, Mardis ER, Davies SR, Friedman PN, Snider JE, Vickery TL, Reed JP, DeSchryver K, Singh B, Gradishar WJ, Perez EA, Martino S, Citron ML, Norton L, Winer EP, Hudis CA, Carey LA, Bernard PS, Nielsen TO, Perou CM, Ellis MJ, Barry WT. PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance). NPJ Breast Cancer. 2016; 2 Epub 2016 Jan 06
    View PubMed
  28. Twelves C, Cortes J, Kaufman PA, Yelle L, Awada A, Binder TA, Olivo M, Song J, O'Shaughnessy JA, Jove M, Perez EA. "New" metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy. Breast Cancer Res. 2015 Dec 09; 17 (1):150
    View PubMed
  29. Cortes J, Hudgens S, Twelves C, Perez EA, Awada A, Yelle L, McCutcheon S, Kaufman PA, Forsythe A, Velikova G. Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial. Breast Cancer Res Treat. 2015 Dec; 154 (3):509-20 Epub 2015 Nov 14
    View PubMed
  30. Solin LJ, Gray R, Hughes LL, Wood WC, Lowen MA, Badve SS, Baehner FL, Ingle JN, Perez EA, Recht A, Sparano JA, Davidson NE. Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study. J Clin Oncol. 2015 Nov 20; 33: (33)3938-44.
    View PubMed
  31. Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Perez EA, Olson JA Jr, Zujewski J, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin P, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Atkins JN, Berenberg JL, Sledge GW. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med. 2015 Nov 19; 373: (21)2005-14.
    View PubMed
  32. Perez EA, Awada A, O'Shaughnessy J, Rugo HS, Twelves C, Im SA, Gomez-Pardo P, Schwartzberg LS, Dieras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, Cortes J. Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2015 Nov; 16: (15)1556-68.
    View PubMed
  33. Coleman R, Powles T, Paterson A, Gnant M, Anderson S, Diel I, Gralow J, von Minckwitz G, Moebus V, Bergh J, Pritchard KI, Bliss J, Cameron D, Evans V, Pan H, Peto R, Bradley R, Gray R, Bartsch R, Dubsky P, Fesl C, Fohler H, Gnant M, Greil R, Jakesz R, Lang A, Luschin-Ebengreuth G, Marth C, Mlineritsch B, Samonigg H, Singer CF, Steger GG, Stoger H, Olivotto I, Ragaz J, Christiansen P, Ejlertsen B, Ewertz M, Jensen MB, Moller S, Mouridsen HT, Eiermann W, Hilfrich J, Jonat W, Kaufmann M, Kreienberg R, Schumacher M, Blohmer JU, Costa SD, Eidtmann H, Gerber B, Jackisch C, Loibl S, von Minckwitz G, Dafni U, Markopoulos C, Blomqvist C, Saarto T, Ahn JH, Jung KH, Perrone F, Anderson S, Bass G, Brown A, Bryant J, Costantino J, Dignam J, Fisher B, Geyer C, Mamounas EP, Paik S, Redmond C, Swain S, Wickerham L, Wolmark N, Perez E, Ingle JN, Suman VJ, Hadji P, A'Hern R, Dowsett M, Makris A, Parton M, Pennert K, Powles TJ, Smith IE, Yarnold JR, Clack G, Van Poznak C, Safra T, Bell R, Cameron D, Coleman RE, Dodwell D, Hinsley S, Marshall HC, Solomayer E, Fehm T, Coleman RE, Lester J, Winter MC, Horsman JM, Aft R, Brufsky AM, Coleman R, Llombart HA. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet. 2015 Oct 3; 386(10001):1353-61.
    View PubMed
  34. Perez EA, Baehner FL, Butler SM, Thompson EA, Dueck AC, Jamshidian F, Cherbavaz D, Yoshizawa C, Shak S, Kaufman PA, Davidson NE, Gralow J, Asmann YW, Ballman KV. The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831. Breast Cancer Res. 2015 Oct 01; 17 (1):133
    View PubMed
  35. Valdivieso M, Corn BW, Dancey JE, Wickerham DL, Horvath LE, Perez EA, Urton A, Cronin WM, Field E, Lackey E, Blanke CD. The Globalization of Cooperative Groups. Semin Oncol. 2015 Oct; 42: (5)693-712.
    View PubMed
  36. Kourtidis A, Ngok SP, Pulimeno P, Feathers RW, Carpio LR, Baker TR, Carr JM, Yan IK, Borges S, Perez EA, Storz P, Copland JA, Patel T, Thompson EA, Citi S, Anastasiadis PZ. Distinct E-cadherin-based complexes regulate cell behaviour through miRNA processing or Src and p120 catenin activity. Nat Cell Biol. 2015 Sep; 17: (9)1145-57.
    View PubMed
  37. Chumsri S, Weidler J, Ali S, Balasubramanian S, Wallweber G, DeFazio-Eli L, Chenna A, Huang W, DeRidder A, Goicocheal L, Perez EA. Prolonged Response to Trastuzumab in a Patient With HER2-Nonamplified Breast Cancer With Elevated HER2 Dimerization Harboring an ERBB2 S310F Mutation. J Natl Compr Canc Netw. 2015 Sep; 13: (9)1066-70.
    View PubMed
  38. Yardley DA, Krop IE, LoRusso PM, Mayer M, Barnett B, Yoo B, Perez EA. Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents: Results From the T-PAS Expanded Access Study. Cancer J. 2015 Sep-Oct; 21: (5)357-64.
    View PubMed
  39. O'Sullivan CC, Bradbury I, Campbell C, Spielmann M, Perez EA, Joensuu H, Costantino JP, Delaloge S, Rastogi P, Zardavas D, Ballman KV, Holmes E, de Azambuja E, Piccart-Gebhart M, Zujewski JA, Gelber RD. Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors <= 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials. J Clin Oncol. 2015 Aug 20; 33: (24)2600-8.
    View PubMed
  40. Wagner-Johnston ND, Sloan JA, Liu H, Kearns AE, Hines SL, Puttabasavaiah S, Dakhil SR, Lafky JM, Perez EA, Loprinzi CL. 5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial. Cancer. 2015 Aug 01; 121 (15):2537-43 Epub 2015 Apr 30
    View PubMed
  41. Rugo HS, Barry WT, Moreno-Aspitia A, Lyss AP, Cirrincione C, Leung E, Mayer EL, Naughton M, Toppmeyer D, Carey LA, Perez EA, Hudis C, Winer EP. Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance). J Clin Oncol. 2015 Jul 20; 33 (21):2361-9 Epub 2015 June 08
    View PubMed
  42. Sparano JA, Zhao F, Martino S, Ligibel JA, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE. Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer. J Clin Oncol. 2015 Jul 20; 33: (21)2353-60.
    View PubMed
  43. Ingle JN, Kalari KR, Buzdar AU, Robson ME, Goetz MP, Desta Z, Barman P, Dudenkov TT, Northfelt DW, Perez EA, Flockhart DA, Williard CV, Wang L, Weinshilboum RM. Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole. Steroids. 2015 Jul; 99: (Pt A)32-8.
    View PubMed
  44. Dueck AC, Singh J, Atherton P, Liu H, Novotny P, Hines S, Loprinzi CL, Perez EA, Tan A, Burger K, Zhao X, Diekmann B, Sloan JA, Alliance for Clinical Trials in Oncology. Endpoint comparison for bone mineral density measurements in North Central Cancer Treatment Group cancer clinical trials N02C1 and N03CC (Alliance). Osteoporos Int. 2015 Jul; 26: (7)1971-7.
    View PubMed
  45. Borges S, Perez EA, Thompson EA, Radisky DC, Geiger XJ, Storz P. Effective Targeting of Estrogen Receptor-Negative Breast Cancers with the Protein Kinase D Inhibitor CRT0066101. Mol Cancer Ther. 2015 Jun; 14: (6)1306-16.
    View PubMed
  46. Perez EA, Thompson EA, Ballman KV, Anderson SK, Asmann YW, Kalari KR, Eckel-Passow JE, Dueck AC, Tenner KS, Jen J, Fan JB, Geiger XJ, McCullough AE, Chen B, Jenkins RB, Sledge GW, Winer EP, Gralow JR, Reinholz MM. Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial. J Clin Oncol. 2015 Mar 01; 33 (7):701-8 Epub 2015 Jan 20
    View PubMed
  47. Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Velikova G, Olivo MS, He Y, Dutcus CE, Cortes J. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2015 Feb 20; 33 (6):594-601 Epub 2015 Jan 20
    View PubMed
  48. Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, Perez EA, Thompson EA, Symmans WF, Richardson AL, Brock J, Criscitiello C, Bailey H, Ignatiadis M, Floris G, Sparano J, Kos Z, Nielsen T, Rimm DL, Allison KH, Reis-Filho JS, Loibl S, Sotiriou C, Viale G, Badve S, Adams S, Willard-Gallo K, Loi S, International TILs Working Group 2014. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015 Feb; 26 (2):259-71 Epub 2014 Sept 11
    View PubMed
  49. Advani PP, Crozier JA, Perez EA. HER2 testing and its predictive utility in anti-HER2 breast cancer therapy. Biomark Med. 2015; 9(1):35-49.
    View PubMed
  50. Liu SZ, Chapman JAW, Burnell MJ, Levine MN, Pritchard KI, Whelan TJ, Rugo HS, Albain KS, Perez EA, Virk S, Barry G, Gao DX, O'Brien P, Shepherd LE, Nielsen TO, Gelmon KA. Prognostic and predictive investigation of pam50 intrinsic subtypes in the ncic ctg ma.21 phase iii chemotherapy trial. Breast Cancer Res Treat. 2015 Jan; 149(2):439-48.
    View PubMed
  51. Lohmann AE, Chapman JAW, Burnell MJ, Levine MN, Tsvetkova E, Pritchard KI, Gelmon KA, O’Brien P, Han L, Rugo HS, Albain KS, Perez EA, Vandenberg TA, Chalchal HI, Sawhney RPS, Shepherd LE, Goodwin PJ. Prognostic associations of 25 hydroxy vitamin D in NCIC CTG MA.21, a phase III adjuvant randomized clinical trial of three chemotherapy regimens in high-risk breast cancer. Breast Cancer Res Treat. 2015; 150(3):605-11.
    View PubMed
  52. Zhu W, Perez EA, Hong R, Li Q, Xu B. Age-Related Disparity in Immediate Prognosis of Patients with Triple-Negative Breast Cancer: A Population-Based Study from SEER Cancer Registries. PLoS One. 2015; 10: (5)e0128345.
    View PubMed
  53. Necela BM, Crozier JA, Andorfer CA, Lewis-Tuffin L, Kachergus JM, Geiger XJ, Kalari KR, Serie DJ, Sun Z, Moreno-Aspitia A, O'Shannessy DJ, Maltzman JD, McCullough AE, Pockaj BA, Cunliffe HE, Ballman KV, Thompson EA, Perez EA. Folate receptor-alpha (FOLR1) expression and function in triple negative tumors. PLoS One. 2015; 10: (3)e0122209.
    View PubMed
  54. Perez EA. Highlights in breast cancer from the 2015 American Society of Clinical Oncology annual meeting. Clin. adv. hematol. oncol. 2015; 13(7).
  55. Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE Jr, Martino S, Rastogi P, Gralow J, Swain SM, Winer EP, Colon-Otero G, Davidson NE, Mamounas E, Zujewski JA, Wolmark N. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014 Nov 20; 32 (33):3744-52 Epub 2014 Oct 20
    View PubMed
  56. Patel TA, Dave B, Rodriguez AA, Chang JC, Perez EA, Colon-Otero G. Erratum: Dual HER2 blockade: preclinical and clinical data. Breast Cancer Res. 2014 Nov 06; 16 (6):468
    View PubMed
  57. Norton N, Olson RM, Pegram M, Tenner K, Ballman KV, Clynes R, Knutson KL, Perez EA. Association studies of Fcgamma receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831. Cancer Immunol Res. 2014 Oct; 2 (10):962-9 Epub 2014 July 02
    View PubMed
  58. Schink JC, Trosman JR, Weldon CB, Siziopikou KP, Tsongalis GJ, Rademaker AW, Patel JD, Benson AB 3rd, Perez EA, Gradishar WJ. Biomarker testing for breast, lung, and gastroesophageal cancers at NCI designated cancer centers. J Natl Cancer Inst. 2014 Oct; 106: (10).
    View PubMed
  59. Crozier JA, Perez EA. Perspectives from the American Society of Clinical Oncology 2014 Conference: breast cancer highlights. Future Oncol. 2014 Oct; 10(12):1897-9.
    View PubMed
  60. Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ, Wolff AC, Wood WC, Davidson NE, Sledge GW, Sparano JA, Badve SS. Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014 Sept 20; 32(27):2959-2966. Epub 2014 Jul 28
    View PubMed
  61. Gray RJ, Zujewski JA, Whelan TJ, Albain KS, Hayes D, Geyer CE, Dees EC, Perez EA, Keane MM, Vallejos Sologuren C, Goggins TF, Mayer IA, Brufsky A, Toppmeyer DL, Kaklamani VG, Atkins JN, Berenberg JL, Sledge GW. Recurrence score and clinicopathologic characteristics of TAILORx participants by race and ethnicity. J Clin Oncol. 2014 Sep 10; 32: (26_suppl)36.
    View PubMed
  62. Cheng H, Ballman K, Vassilakopoulou M, Dueck AC, Reinholz MM, Tenner K, Gralow J, Hudis C, Davidson NE, Fountzilas G, McCullough AE, Chen B, Psyrri A, Rimm DL, Perez EA. EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial. Br J Cancer. 2014 Sep 09; 111 (6):1065-71 Epub 2014 Aug 12
    View PubMed
  63. Schneider BP, Li L, Shen F, Miller KD, Radovich M, O'Neill A, Gray RJ, Lane D, Flockhart DA, Jiang G, Wang Z, Lai D, Koller D, Pratt JH, Dang CT, Northfelt D, Perez EA, Shenkier T, Cobleigh M, Smith ML, Railey E, Partridge A, Gralow J, Sparano J, Davidson NE, Foroud T, Sledge GW. Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100. Br J Cancer. 2014 Sep 09; 111: (6)1241-8.
    View PubMed
  64. de Azambuja E, Holmes AP, Piccart-Gebhart M, Holmes E, Di Cosimo S, Swaby RF, Untch M, Jackisch C, Lang I, Smith I, Boyle F, Xu B, Barrios CH, Perez EA, Azim HA Jr, Kim SB, Kuemmel S, Huang CS, Vuylsteke P, Hsieh RK, Gorbunova V, Eniu A, Dreosti L, Tavartkiladze N, Gelber RD, Eidtmann H, Baselga J. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol. 2014 Sep; 15: (10)1137-46.
    View PubMed
  65. Andersson M, Lopez-Vega JM, Petit T, Zamagni C, Freudensprung U, Robb S, Restuccia E, Perez EA. 361PDINTERIM SAFETY AND EFFICACY OF PERTUZUMAB, TRASTUZUMAB AND VINORELBINE FOR FIRST-LINE (1L) TREATMENT OF PATIENTS (PTS) WITH HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (MBC). Ann Oncol. 2014 Sep 01; 25: (suppl_4)iv120.
    View PubMed
  66. Shulman LN, Berry DA, Cirrincione CT, Becker HP, Perez EA, O'Regan R, Martino S, Shapiro CL, Schneider CJ, Kimmick G, Burstein HJ, Norton L, Muss H, Hudis CA, Winer EP. Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). J Clin Oncol. 2014 Aug 01; 32 (22):2311-7 Epub 2014 June 16
    View PubMed
  67. Patel TA, Dave B, Rodriguez AA, Chang JC, Perez EA, Colon-Otero G. Dual HER2 blockade: preclinical and clinical data. Breast Cancer Res. 2014 Aug 01; 16: (4)419.
    View PubMed
  68. Ramakrishna N, Temin S, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, Giordano SH, Gonzalez-Angulo AM, Kirshner JJ, Krop I, Levinson J, Modi S, Patt DA, Perez EA, Perlmutter J, Winer EP, Lin NU. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014 Jul 1; 32(19):2100-8. Epub 2014 May 05.
    View PubMed
  69. Giordano SH, Temin S, Kirshner JJ, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, Gonzalez-Angulo AM, Krop I, Levinson J, Lin NU, Modi S, Patt DA, Perez EA, Perlmutter J, Ramakrishna N, Winer EP, American Society of Clinical Oncology. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014 Jul 01; 32: (19)2078-99.
    View PubMed
  70. Perez EA. Highlights in breast cancer from the 2014 American Society of Clinical Oncology(R) annual meeting. Clin Adv Hematol Oncol. 2014 Jul; 12(7):451-3.
    View PubMed
  71. Regan MM, Walley B, Fleming GF, Colleoni M, Lang I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE, Rabaglio-Poretti M, Coates AS, Gelber RD, Goldhirsch A, Francis PA. Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Joint analysis of IBCSG TEXT and SOFT trials. J Clin Oncol. 2014 Jun 20; 32: (18_suppl)LBA1.
    View PubMed
  72. Holmes AP, Baselga J, De Azambuja E, Dueck AC, Viale G, Zujewski JA, Goldhirsch A, Santillana S, Pritchard KI, Wolff AC, Jackisch C, Lang I, Untch M, Smith IE, Boyle F, Xu B, Gomez HL, Gelber RD, Perez EA. First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T-->L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC). J Clin Oncol. 2014 Jun 20; 32: (18_suppl)LBA4.
    View PubMed
  73. Northfelt DW, Allred JB, Liu H, Hobday TJ, Rodacker MW, Lyss AP, Fitch TR, Perez EA, North Central Cancer Treatment Group. Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer. Am J Clin Oncol. 2014 Apr; 37 (2):167-71
    View PubMed
  74. Perez EA, Cortes J, Gonzalez-Angulo AM, Bartlett JM. HER2 testing: current status and future directions. Cancer Treat Rev. 2014 Mar; 40(2):276-84. Epub 2013 Sep 11
    View PubMed
  75. McCullough AE, Dell'orto P, Reinholz MM, Gelber RD, Dueck AC, Russo L, Jenkins RB, Andrighetto S, Chen B, Jackisch C, Untch M, Perez EA, Piccart-Gebhart MJ, Viale G. Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06NCCTG N063D (Alliance)] ring study. Breast Cancer Res Treat. 2014 Feb; 143: (3)485-92.
    View PubMed
  76. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF, American Society of Clinical Oncology//College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical OncologyCollege of American Pathologists clinical practice guideline update. Arch Pathol Lab Med. 2014 Feb; 138: (2)241-56.
    View PubMed
  77. Ignatiadis M, Riethdorf S, Bidard FC, Vaucher I, Khazour M, Rothe F, Metallo J, Rouas G, Payne RE, Coombes RC, Teufel I, Andergassen U, Apostolaki S, Politaki E, Mavroudis D, Bessi S, Pestrin M, Di Leo A, Campion M, Reinholz M, Perez E, Piccart M, Borgen E, Naume B, Jimenez J, Aura CM, Zorzino L, Cassatella MC, Sandri MT, Mostert B, Sleijfer S, Kraan J, Janni W, Fehm T, Rack B, Terstappen L, Repollet M, Pierga JY, Miller C, Sotiriou C, Michiels S, Pantel K. International study on inter-reader variability for circulating tumor cells in breast cancer. Breast Cancer Res. 2014; 16(2):R43.
    View PubMed
  78. Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Lang I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE Jr, Pinotti G, Puglisi F, Crivellari D, Ruhstaller T, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Bernhard J, Luo W, Ribi K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014; 371(2):107-18.
    View PubMed
  79. Perez EA, Hurvitz SA, Amler LC, Mundt KE, Ng V, Guardino E, Gianni L. Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: A randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer. Breast Cancer Res. 2014; 16:R50.
    View PubMed
  80. Roy V, Pockaj BA, Allred JB, Apsey H, Northfelt DW, Nikcevich D, Mattar B, Perez EA. A Phase II trial of docetaxel and carboplatin administered every 2 weeks as preoperative therapy for stage II or III breast cancer: NCCTG study N0338. Am J Clin Oncol. 2013 Dec; 36: (6)540-4.
    View PubMed
  81. Awada A, Garcia AA, Chan S, Jerusalem GH, Coleman RE, Huizing MT, Mehdi A, O'Reilly SM, Hamm JT, Barrett-Lee PJ, Cocquyt V, Sideras K, Young DE, Zhao C, Chia YL, Hoch U, Hannah AL, Perez EA, NKTR-102 Study Group. Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study. Lancet Oncol. 2013 Nov; 14(12):1216-25. Epub 2013 Oct 04.
    View PubMed
  82. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF, American Society of Clinical Oncology, College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013 Nov 1; 31(31):3997-4013. Epub 2013 Oct 07.
    View PubMed
  83. Dueck AC, Reinholz MM, Geiger XJ, Tenner K, Ballman K, Jenkins RB, Riehle D, Chen B, McCullough AE, Davidson NE, Martino S, Sledge GW, Kaufman PA, Kutteh LA, Gralow J, Harris LN, Ingle JN, Lingle WL, Perez EA. Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831. Clin Cancer Res. 2013 Oct 15; 19: (20)5798-807.
    View PubMed
  84. Tan WW, Dueck AC, Flynn P, Steen P, Anderson D, Rowland K, Northfelt D, Perez EA. N0539 phase II trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Treatment Group (now Alliance) trial. Ann Oncol. 2013 Oct; 24: (10)2548-54.
    View PubMed
  85. Rugo HS, Perez EA, Vahdat LT. New developments in metastatic breast cancer: general discussion. Clin Adv Hematol Oncol. 2013 Oct; 11(10 Suppl 16):16-7.
    View PubMed
  86. Krop IE, LoRusso P, Robert NJ, Mayer M, Abidoye OO, Lai C, Yoo B, Perez EA. Trastuzumab emtansine (T-DM1) in previously treated HER2-positive metastatic breast cancer (MBC): Results from an expanded access study. J Clin Oncol. 2013 Sep 10; 31: (26_suppl)166.
    View PubMed
  87. Borges S, Doppler H, Perez EA, Andorfer CA, Sun Z, Anastasiadis PZ, Thompson EA, Geiger XJ, Storz P. Pharmacologic reversion of epigenetic silencing of the PRKD1 promoter blocks breast tumor cell invasion and metastasis. Breast Cancer Res. 2013 Aug 23; 15(2):R66.
    View PubMed
  88. Moreno-Aspitia A, Hillman DW, Dyar SH, Tenner KS, Gralow J, Kaufman PA, Davidson NE, Lafky JM, Reinholz MM, Lingle WL, Kutteh LA, Carney WP, Dueck AC, Perez EA. Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831. Cancer. 2013 Aug 1; 119: (15)2675-82.
    View PubMed
  89. Perez EA, Gradishar WJ, Twelves C, Schwartzberg L. Individualizing treatment to optimize survival outcomes in breast cancer. Clin Adv Hematol Oncol. 2013 Aug; 11 Suppl 10(8):3-21.
    View PubMed
  90. Crozier JA, Moreno-Aspitia A, Ballman KV, Dueck AC, Pockaj BA, Perez EA. Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831. Cancer. 2013 Jul 1; 119: (13)2447-54.
    View PubMed
  91. Perez EA, Dueck AC, McCullough AE, Chen B, Geiger XJ, Jenkins RB, Lingle WL, Davidson NE, Martino S, Kaufman PA, Kutteh LA, Sledge GW, Harris LN, Gralow JR, Reinholz MM. Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial. J Clin Oncol. 2013 Jun 10; 31: (17)2115-22.
    View PubMed
  92. Solin LJ, Gray R, Baehner FL, Butler SM, Hughes LL, Yoshizawa C, Cherbavaz DB, Shak S, Page DL, Sledge GW, Davidson NE, Ingle JN, Perez EA, Wood WC, Sparano JA, Badve S. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2013 May 15; 105(10):701-10. Epub 2013 May 02.
    View PubMed
  93. Goss PE, Ingle JN, Pritchard KI, Ellis MJ, Sledge GW, Budd GT, Rabaglio M, Ansari RH, Johnson DB, Tozer R, D'Souza DP, Chalchal H, Spadafora S, Stearns V, Perez EA, Liedke PE, Lang I, Elliott C, Gelmon KA, Chapman JA, Shepherd LE. Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial. J Clin Oncol. 2013 Apr 10; 31(11):1398-404. Epub 2013 Jan 28.
    View PubMed
  94. Moreno-Aspitia A, Dueck AC, Ghanem-Canete I, Patel T, Dakhil S, Johnson D, Franco S, Kahanic S, Colon-Otero G, Tenner KS, Rodeheffer R, McCullough AE, Jenkins RB, Palmieri FM, Northfelt D, Perez EA. RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer. Breast Cancer Res Treat. 2013 Apr; 138: (2)427-35.
    View PubMed
  95. Liu M, Ingle JN, Fridley BL, Buzdar AU, Robson ME, Kubo M, Wang L, Batzler A, Jenkins GD, Pietrzak TL, Carlson EE, Goetz MP, Northfelt DW, Perez EA, Williard CV, Schaid DJ, Nakamura Y, Weinshilboum RM. TSPYL5 SNPs: association with plasma estradiol concentrations and aromatase expression. Mol Endocrinol. 2013 Apr; 27: (4)657-70.
    View PubMed
  96. Hurvitz SA, Dirix L, Kocsis J, Bianchi GV, Lu J, Vinholes J, Guardino E, Song C, Tong B, Ng V, Chu YW, Perez EA. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2013 Mar 20; 31(9):1157-63. Epub 2013 Feb 04.
    View PubMed
  97. Schneider BP, Gray RJ, Radovich M, Shen F, Vance G, Li L, Jiang G, Miller KD, Gralow JR, Dickler MN, Cobleigh MA, Perez EA, Shenkier TN, Vang Nielsen, Muller S, Thor A, Sledge GW, Sparano JA, Davidson NE, Badve SS. Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial. Clin Cancer Res. 2013 Mar 1; 19(5):1281-9. Epub 2013 Jan 22.
    View PubMed
  98. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Livingston RB, Davidson NE, Perez EA, Chavarri-Guerra Y, Cameron DA, Pritchard KI, Whelan T, Shepherd LE, Tu D. Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole. Ann Oncol. 2013 Feb; 24(2):355-61. Epub 2012 Oct 01.
    View PubMed
  99. Perez EA, Press MF, Dueck AC, Jenkins RB, Kim C, Chen B, Villalobos I, Paik S, Buyse M, Wiktor AE, Meyer R, Finnigan M, Zujewski J, Shing M, Stern HM, Lingle WL, Reinholz MM, Slamon DJ. Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005). Breast Cancer Res Treat. 2013 Feb; 138: (1)99-108.
    View PubMed
  100. Mahoney DW, Therneau TM, Anderson SK, Jen J, Kocher JP, Reinholz MM, Perez EA, Eckel-Passow JE. Quality assessment metrics for whole genome gene expression profiling of paraffin embedded samples. BMC Res Notes. 2013 Jan 30; 6:33.
    View PubMed
  101. Metzger-Filho O, de Azambuja E, Bradbury I, Saini KS, Bines J, Simon SD, Dooren VV, Aktan G, Pritchard KI, Wolff AC, Smith I, Jackisch C, Lang I, Untch M, Boyle F, Xu B, Baselga J, Perez EA, Piccart-Gebhart M. Analysis of regional timelines to set up a global phase III clinical trial in breast cancer: the adjuvant lapatinib and/or trastuzumab treatment optimization experience. Oncologist. 2013; 18(2):134-40. Epub 2013 Jan 28.
    View PubMed
  102. Sun Z, Asmann YW, Nair A, Zhang Y, Wang L, Kalari KR, Bhagwate AV, Baker TR, Carr JM, Kocher JP, Perez EA, Thompson EA. Impact of library preparation on downstream analysis and interpretation of RNA-Seq data: comparison between Illumina PolyA and NuGEN Ovation protocol. PLoS One. 2013; 8(8):e71745. Epub 2013 Aug 19.
    View PubMed
  103. Garrison LP Jr, Lalla D, Brammer M, Babigumira JB, Wang B, Perez EA. Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status. Cancer. 2013; 119(17):3113-22.
    View PubMed
  104. Kalari KR, Necela BM, Tang X, Thompson KJ, Lau M, Eckel-Passow JE, Kachergus JM, Anderson SK, Sun Z, Baheti S, Carr JM, Baker TR, Barman P, Radisky DC, Joseph RW, McLaughlin SA, Chai HS, Camille S, Rossell D, Asmann YW, Thompson EA, Perez EA. An integrated model of the transcriptome of HER2-positive breast cancer. PLoS One. 2013; 8: (11)e79298.
    View PubMed
  105. Norton N, Sun Z, Asmann YW, Serie DJ, Necela BM, Bhagwate A, Jen J, Eckloff BW, Kalari KR, Thompson KJ, Carr JM, Kachergus JM, Geiger XJ, Perez EA, Thompson EA. Gene expression, single nucleotide variant and fusion transcript discovery in archival material from breast tumors. PLoS One. 2013; 8(11):e81925. Epub 2013 Nov 22.
    View PubMed
  106. Norton N, Perez EA. How relevant is hormone receptor status in the context of outcome to HER2-positive breast cancer? Breast Cancer Res. 2013; 15(1):101. Epub 2013 Jan 14
    View PubMed
  107. Perez EA. Practice-changing data in metastatic breast cancer. Clin Adv Hematol Oncol. 2013; 11: (10 Suppl 16)7-12.
    View PubMed
  108. Sideras K, Dueck AC, Hobday TJ, Rowland KM Jr, Allred JB, Northfelt DW, Lingle WL, Behrens RJ, Fitch TR, Nikcevich DA, Perez EA. North central cancer treatment group (NCCTG) N0537: phase II trial of VEGF-trap in patients with metastatic breast cancer previously treated with an anthracycline and/or a taxane. Clin Breast Cancer. 2012 Dec; 12: (6)387-91.
    View PubMed
  109. Shulman LN, Cirrincione CT, Berry DA, Becker HP, Perez EA, O'Regan R, Martino S, Atkins JN, Mayer E, Schneider CJ, Kimmick G, Norton L, Muss H, Winer EP, Hudis C. Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. J Clin Oncol. 2012 Nov 20; 30(33):4071-6. Epub 2012 Jul 23.
    View PubMed
  110. Vahdat LT, Thomas ES, Roche HH, Hortobagyi GN, Sparano JA, Yelle L, Fornier MN, Martin M, Bunnell CA, Mukhopadhyay P, Peck RA, Perez EA. Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials. Support Care Cancer. 2012 Nov; 20(11):2661-8. Epub 2012 Mar 02.
    View PubMed
  111. Cooper SJ, von Roemeling CA, Kang KH, Marlow LA, Grebe SK, Menefee ME, Tun HW, Colon-Otero G, Perez EA, Copland JA. Reexpression of tumor suppressor, sFRP1, leads to antitumor synergy of combined HDAC and methyltransferase inhibitors in chemoresistant cancers. Mol Cancer Ther. 2012 Oct; 11: (10)2105-15.
    View PubMed
  112. Hurvitz SA, Perez EA, Yamamoto H, Valero V, O'Neill V, Rugo HS. Final overall survival (OS) and safety analyses of RIBBON-2, a randomized phase III trial of bevacizumab (BEV) versus placebo (PL) combined with second-line chemotherapy (CT) for HER2-negative BEV-naive metastatic breast cancer (MBC). J Clin Oncol. 2012 Sep 20; 30: (27_suppl)100.
    View PubMed
  113. Perez EA. Highlights in metastatic breast cancer from the 2012 American Society of Clinical Oncology Annual Meeting. Clin Adv Hematol Oncol. 2012 Sep; 10(9 Suppl 14):1-24.
    View PubMed
  114. Perez EA, Burris HA 3rd, Mooberry S, Tripathy D. New treatment paradigms for optimizing survival in advanced and metastatic breast cancer. Clin Adv Hematol Oncol. 2012 Aug; 10(8 Suppl 13):1-14; quiz 15-6.
    View PubMed
  115. Schneider BP, Zhao F, Wang M, Stearns V, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW, Wood WC, Davidson NE, Sparano JA. Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer. J Clin Oncol.2012;
    View PubMed
  116. Solin LJ, Gray R, Goldstein LJ, Recht A, Baehner FL, Shak S, Badve S, Perez EA, Shulman LN, Martino S, Davidson NE, Sledge GW Jr, Sparano JA. Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study. Breast Cancer Res Treat. 2012 Jul; 134(2):683-92. Epub 2012 May 01.
    View PubMed
  117. Paterson AH, Anderson SJ, Lembersky BC, Fehrenbacher L, Falkson CI, King KM, Weir LM, Brufsky AM, Dakhil S, Lad T, Baez-Diaz L, Gralow JR, Robidoux A, Perez EA, Zheng P, Geyer CE, Swain SM, Costantino JP, Mamounas EP, Wolmark N. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol. 2012 Jul; 13(7):734-42. Epub 2012 Jun 14.
    View PubMed
  118. Li T, Guo M, Gradishar WJ, Sparano JA, Perez EA, Wang M, Sledge GW. A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103). Breast Cancer Res Treat. 2012 Jul; 134(1):345-52. Epub 2012 May 01.
    View PubMed
  119. Perez EA. Next-generation targeted agents in HER2-positive metastatic breast cancer. Clin Adv Hematol Oncol. 2012 Jul; 10(7):465-7.
    View PubMed
  120. Burstein HJ, Piccart-Gebhart MJ, Perez EA, Hortobagyi GN, Wolmark N, Albain KS, Norton L, Winer EP, Hudis CA. Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines? J Clin Oncol. 2012 Jun 20; 30(18):2179-82. Epub 2012 May 21.
    View PubMed
  121. Tang G, Geyer CE, Rastogi P, Atkins JN, Donnellan PP, Fehrenbacher L, Azar CA, Robidoux A, Polikoff J, Brufsky A, Biggs DD, Levine EA, Zapas JL, Provencher L, Perez EA, Paik S, Costantino JP, Mamounas EP, Wolmark N. NSABP B-38: Definitive analysis of a randomized adjuvant trial comparing dose-dense (DD) AC-->paclitaxel (P) plus gemcitabine (G) with DD AC-->P and with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with operable, node-positive breast cancer. J Clin Oncol. 2012 Jun 20; 30: (18_suppl)LBA1000.
    View PubMed
  122. Barry WT, Moreno-Aspitia A, Lyss AP, Cirrincione C, Mayer EL, Naughton M, Layman RM, Carey LA, Somer RA, Perez EA, Hudis C, Winer EP. CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC). J Clin Oncol. 2012 Jun 20; 30: (18_suppl)CRA1002.
    View PubMed
  123. Perez EA, Spano JP. Current and emerging targeted therapies for metastatic breast cancer. Cancer. 2012 Jun 15; 118(12):3014-25. Epub 2011 Oct 17.
    View PubMed
  124. Asmann YW, Necela BM, Kalari KR, Hossain A, Baker TR, Carr JM, Davis C, Getz JE, Hostetter G, Li X, McLaughlin SA, Radisky DC, Schroth GP, Cunliffe HE, Perez EA, Thompson EA. Detection of redundant fusion transcripts as biomarkers or disease-specific therapeutic targets in breast cancer. Cancer Res. 2012 Apr 15; 72(8):1921-8. Epub 2012 Apr 10.
    View PubMed
  125. Tan WW, Allred JB, Salim M, Flynn P, Fishkin PA, Stella PJ, Wiesenfeld M, Bernath AM, Fitch TR, Perez EA. Phase II interventional study (N0337) of capecitabine in combination with vinorelbine and trastuzumab for first- or second-line treatment of HER2-positive metastatic breast cancer: a north central cancer treatment group trial. Clin Breast Cancer. 2012 Apr; 12 (2):81-6
    View PubMed
  126. Sparano JA, Wang M, Zhao F, Stearns V, Martino S, Ligibel JA, Perez EA, Saphner T, Wolff AC, Sledge GW, Wood WC, Davidson NE. Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial. J Natl Cancer Inst. 2012 Mar 7; 104(5):406-14. Epub 2012 Jan 16.
    View PubMed
  127. Brufsky AM, Harker WG, Beck JT, Bosserman L, Vogel C, Seidler C, Jin L, Warsi G, Argonza-Aviles E, Hohneker J, Ericson SG, Perez EA. Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer. 2012 Mar 1; 118(5):1192-201. Epub 2011 Oct 10.
    View PubMed
  128. Miller KD, O'Neill A, Perez EA, Seidman AD, Sledge GW. A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group. Ann Oncol. 2012 Feb; 23(2):331-7. Epub 2011 Aug 04.
    View PubMed
  129. Perez EA, Dueck AC, McCullough AE, Reinholz MM, Tenner KS, Davidson NE, Gralow J, Harris LN, Kutteh LA, Hillman DW, Jenkins RB, Chen B. Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCOCAP HER2-positivity criteria. J Natl Cancer Inst. 2012 Jan 18; 104: (2)159-62.
    View PubMed
  130. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2012 Jan; 9(1):16-32. Epub 2011 Nov 29.
    View PubMed
  131. Kalari KR, Rossell D, Necela BM, Asmann YW, Nair A, Baheti S, Kachergus JM, Younkin CS, Baker T, Carr JM, Tang X, Walsh MP, Chai HS, Sun Z, Hart SN, Leontovich AA, Hossain A, Kocher JP, Perez EA, Reisman DN, Fields AP, Thompson EA. Deep Sequence Analysis of Non-Small Cell Lung Cancer: Integrated Analysis of Gene Expression, Alternative Splicing, and Single Nucleotide Variations in Lung Adenocarcinomas with and without Oncogenic KRAS Mutations. Front Oncol. 2012; 2:12.
    View PubMed
  132. Maynard JR, Taylor WC III, McNeil RB, Shapiro SA, Mohseni MM, Vadeboncoeur TF, Silvers SM, Sumrall SV, Perez EA, Diehl NN. Impact of race pace on development of hyponatremia in full- and half-marathoners. S Afr J Med. 2012; 24(2):36-42.
  133. Sparano JA, Wang M, Zhao F, Stearns V, Martino S, Ligibel JA, Perez EA, Saphner T, Wolff AC, Sledge GW, Wood WC, Fetting J, Davidson NE. Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. Cancer. 2012; 118(23):5937-46.
    View PubMed
  134. Strizzi L, Hardy KM, Margaryan NV, Hillman DW, Seftor EA, Chen B, Geiger XJ, Thompson EA, Lingle WL, Andorfer CA, Perez EA, Hendrix MJ. Potential for the embryonic morphogen Nodal as a prognostic and predictive biomarker in breast cancer. Breast Cancer Res. 2012; 14(3):R75. Epub 2012 May 11.
    View PubMed
  135. Perez EA, Suman VJ, Davidson NE, Gralow JR, Kaufman PA, Visscher DW, Chen B, Ingle JN, Dakhil SR, Zujewski J, Moreno-Aspitia A, Pisansky TM, Jenkins RB. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol. 2011 Dec 01; 29: (34)4491-7.
    View PubMed
  136. Reinholz MM, Kitzmann KA, Tenner K, Hillman D, Dueck AC, Hobday TJ, Northfelt DW, Moreno-Aspitia A, Roy V, LaPlant B, Allred JB, Stella PJ, Lingle WL, Perez EA. Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North Central Cancer Treatment Group trials, N0234/336/436/437. Clin Cancer Res. 2011 Nov 15; 17 (22):7183-93 Epub 2011 Oct 05
    View PubMed
  137. Sparano JA, Goldstein LJ, Childs BH, Shak S, Brassard D, Badve S, Baehner FL, Bugarini R, Rowley S, Perez EA, Shulman LN, Martino S, Davidson NE, Kenny PA, Sledge GW, Gray R. Relationship between quantitative GRB7 RNA expression and recurrence after adjuvant anthracycline chemotherapy in triple-negative breast cancer. Clin Cancer Res. 2011 Nov 15; 17(22):7194-203. Epub 2011 Sep 20.
    View PubMed
  138. Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O'Neill V, Rugo HS. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2011 Nov 10; 29(32):4286-93. Epub 2011 Oct 11.
    View PubMed
  139. Mathew J, Perez EA. Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer: a review. Curr Opin Oncol. 2011 Nov; 23(6):594-600.
    View PubMed
  140. Rugo HS, O'Shaughnessy JA, Perez EA. Clinical roundtable monograph. Current treatment options for metastatic breast cancer: what now? Clin Adv Hematol Oncol. 2011 Nov; 9(11):1-16.
    View PubMed
  141. Schneider BP, Wang M, Stearns V, Martino S, Jones VE, Perez EA, Saphner TJ, Wolff AC, Sledge GW, Wood W, Davidson NE, Sparano JA. Relationship between taxane-induced neuropathy and clinical outcomes after adjuvant chemotherapy. J Clin Oncol. 2011 Sep 20; 29: (27_suppl)270.
    View PubMed
  142. Garcia A, Awada A, Chan S, Jerusalem GH, Coleman RE, Huizing MT, Mehdi A, O'Reilly SM, Hamm JT, Barrett-Lee PJ, Cocquyt V, Sideras K, Young DE, Brown M, Zhao C, Hannah AL, Leung AC, Masuoka LK, Perez EA. Final results of NKTR-102, a topoisomerase I inhibitor-polymer conjugate, in patients (Pts) with pretreated metastatic breast cancer (MBC) demonstrating significant antitumor activity. J Clin Oncol. 2011 Sep 20; 29: (27_suppl)269.
    View PubMed
  143. Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE Jr, Martino S, Mamounas EP, Kaufman PA, Wolmark N. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011 Sep 01; 29: (25)3366-73.
    View PubMed
  144. Asmann YW, Hossain A, Necela BM, Middha S, Kalari KR, Sun Z, Chai HS, Williamson DW, Radisky D, Schroth GP, Kocher JP, Perez EA, Thompson EA. A novel bioinformatics pipeline for identification and characterization of fusion transcripts in breast cancer and normal cell lines. Nucleic Acids Res. 2011 Aug; 39(15):e100. Epub 2011 May 27.
    View PubMed
  145. Perez EA, Mooberry S, Twelves C, Rugo HS. New frontiers and treatment paradigms for metastatic breast cancer. A Review of an adjunct symposium of the 2011 American Society of Clinical Oncology Annual Meeting, June 4, 2011 Chicago, Illinois. Clin Adv Hematol Oncol. 2011 Aug; 9(8 Suppl 20):1-15.
    View PubMed
  146. Adkisson CD, Vallow LA, Kowalchik K, McNeil R, Hines S, Deperi E, Moreno A, Roy V, Perez EA, McLaughlin SA. Patient age and preoperative breast MRI in women with breast cancer: biopsy and surgical implications. Ann Surg Oncol. 2011 Jun; 18(6):1678-83. Epub 2011 Jan 05.
    View PubMed
  147. Andorfer CA, Necela BM, Thompson EA, Perez EA. MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer. Trends Mol Med. 2011 Jun; 17(6):313-9. Epub 2011 Mar 02.
    View PubMed
  148. Block MS, Suman V, Kosel ML, Markovic S, Northfelt DW, Mukherjee P, McCullough AE, Pockaj BA, Nevala WK, Ingle JN, Perez EA, Gendler SJ. MUC1/HER2/neu peptide-based immunotherapeutic vaccines for breast adenocarcinomas. J Clin Oncol. 2011 May 20; 29: (15_suppl)e13046.
    View PubMed
  149. Awada A, Chan S, Jerusalem GH, Coleman RE, Huizing MT, Mehdi A, O'Reilly SM, Hamm JT, Barrett-Lee PJ, Cocquyt V, Sideras K, Young DE, Brown M, Zhao C, Hannah AL, Masuoka LK, Garcia A, Perez EA, NKTR-102 Study Group. Antitumor activity in a randomized phase II study comparing two schedules of NKTR-102 in patients (Pts) with pretreated metastatic breast cancer (MBC). J Clin Oncol. 2011 May 20; 29: (15_suppl)1034.
    View PubMed
  150. Ingle JN, Fridley BL, Buzdar A, Robson ME, Kubo M, Liu M, Ibrahim-Zada I, Batzler A, Jenkins GD, Goetz MP, Northfelt DW, Perez EA, Williard CV, Wang L, Schaid DJ, Nakamura Y, Weinshilboum RM. Genes regulating estradiol and estrone-conjugate levels in postmenopausal women with resected early-stage breast cancer detected by a genome-wide association study (GWAS). J Clin Oncol. 2011 May 20; 29: (15_suppl)1001.
    View PubMed
  151. Northfelt DW, Dueck AC, Flynn TP, Zander PJ, Stella PJ, Melnik M, Pavey ES, Perez EA. Phase II trial combining nab-paclitaxel (NP), gemcitabine (G), and bevacizumab (B) in patients (pts) with metastatic breast cancer (MBC): NCCTG N0735. J Clin Oncol. 2011 May 20; 29: (15_suppl)1126.
    View PubMed
  152. Perez EA, Dueck AC, Reinholz MM, Chen B, Geiger X, Jenkins RB, Lingle WL, Andorfer C, Davidson NE, Martino S, Kaufman PA, Kutteh LA, Sledge GW, Harris L, Gralow J, McCullough AE. Effect of PTEN protein expression on benefit to adjuvant trastuzumab in early-stage HER2+ breast cancer in NCCTG adjuvant trial N9831. J Clin Oncol. 2011 May 20; 29: (15_suppl)10504.
    View PubMed
  153. Reinholz MM, Dueck AC, Chen B, Geiger X, McCullough AE, Jenkins RB, Lingle WL, Andorfer C, Davidson NE, Martino S, Kaufman PA, Kutteh LA, Sledge GW, Harris L, Gralow J, Perez EA. Effect of IGF1R protein expression on benefit to adjuvant trastuzumab in early-stage HER2+ breast cancer in NCCTG N9831 trial. J Clin Oncol. 2011 May 20; 29: (15_suppl)10503.
    View PubMed
  154. Garrison LP, Lalla D, Brammer MG, Wang B, Babigumira J, Perez EA. Assessing the potential cost-effectiveness of retesting IHC0, IHC1-positive, or FISH-negative early-stage breast cancer patients for HER2 status. J Clin Oncol. 2011 May 20; 29: (15_suppl)6133.
    View PubMed
  155. Ellis PA, Barrios CH, Im Y, Patre M, Branle F, Perez EA. MARIANNE: A phase III, randomized study of trastuzumab-DM1 (T-DM1) with or without pertuzumab (P) compared with trastuzumab (H) plus taxane for first-line treatment of HER2-positive, progressive, or recurrent locally advanced or metastatic breast cancer (MBC). J Clin Oncol. 2011 May 20; 29: (15_suppl)TPS102.
    View PubMed
  156. Mathew J, Vishnu P, Perez EA. Highlights from the 3rd Breast-Gynecological International Cancer Conference 2011. Expert Rev Anticancer Ther. 2011 May; 11: (5)701-4.
    View PubMed
  157. Perez E. New biomarkers for intervention in breast cancer. Clin Adv Hematol Oncol. 2011 May; 9(5 Suppl 11):14-5.
  158. Perez E, Burstein HJ, Hudis C. Recent advances in the treatment of breast cancer: highlights from the 2010 San Antonio Breast Cancer Symposium. Clin Adv Hematol Oncol. 2011 May; 9(5 Suppl 11):1-16.
    View PubMed
  159. Robert NJ, Dieras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, Phan SC, O'Shaughnessy J. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011 Apr 1; 29(10):1252-60. Epub 2011 Mar 07.
    View PubMed
  160. Ganz PA, Land SR, Geyer CE, Cecchini RS, Costantino JP, Pajon ER, Fehrenbacher L, Atkins JN, Polikoff JA, Vogel VG, Erban JK, Livingston RB, Perez EA, Mamounas EP, Wolmark N, Swain SM. Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial. J Clin Oncol. 2011 Mar 20; 29(9):1110-6. Epub 2011 Feb 07.
    View PubMed
  161. Ellis GK, Barlow WE, Gralow JR, Hortobagyi GN, Russell CA, Royce ME, Perez EA, Lew D, Livingston RB. Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012. J Clin Oncol. 2011 Mar 10; 29(8):1014-21. Epub 2011 Jan 10.
    View PubMed
  162. Sun Z, Asmann YW, Kalari KR, Bot B, Eckel-Passow JE, Baker TR, Carr JM, Khrebtukova I, Luo S, Zhang L, Schroth GP, Perez EA, Thompson EA. Integrated analysis of gene expression, CpG island methylation, and gene copy number in breast cancer cells by deep sequencing. PLoS One. 2011 Feb 25; 6: (2)e17490.
    View PubMed
  163. Perez EA, Jenkins RB, Dueck AC, Wiktor AE, Bedroske PP, Anderson SK, Ketterling RP, Sukov WR, Kanehira K, Chen B, Geiger XJ, Andorfer CA, McCullough AE, Davidson NE, Martino S, Sledge GW, Kaufman PA, Kutteh LA, Gralow JR, Harris LN, Ingle JN, Lingle WL, Reinholz MM. C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial. J Clin Oncol. 2011 Feb 20; 29: (6)651-9.
    View PubMed
  164. Roche H, Conte P, Perez EA, Sparano JA, Xu B, Jassem J, Peck R, Kelleher T, Hortobagyi GN. Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies. Breast Cancer Res Treat. 2011 Feb; 125(3):755-65. Epub 2010 Dec 03.
    View PubMed
  165. Perez EA. Breast cancer management: opportunities and barriers to an individualized approach. Oncologist. 2011; 16 Suppl 1:20-2.
    View PubMed
  166. Perez E, Burstein HJ, Hudis C. Clinical Roundtable Monograph: Recent Advances in the Treatment of Breast Cancer: Highlights From the 2010 San Antonio Breast Cancer Symposium Clin. adv. hematol. oncol. 2011; 9(5):Suppl 11.
  167. Perez EA. New treatment strategies in the management of breast cancer. European Journal of Cancer, Supplement. 2011; 9(2):22-9.
  168. Reinholz MM, Eckel-Passow JE, Anderson SK, Asmann YW, Zschunke MA, Oberg AL, McCullough AE, Dueck AC, Chen B, April CS, Wickham-Garcia E, Jenkins RB, Cunningham JM, Jen J, Perez EA, Fan JB, Lingle WL. Expression profiling of formalin-fixed paraffin-embedded primary breast tumors using cancer-specific and whole genome gene panels on the DASL(R) platform. BMC Med Genomics. 2010 Dec 20; 3:60.
    View PubMed
  169. Santana-Davila R, Perez EA. Treatment options for patients with triple-negative breast cancer. J Hematol Oncol. 2010 Oct 27; 3:42.
    View PubMed
  170. Perez EA, Reinholz MM, Hillman DW, Tenner KS, Schroeder MJ, Davidson NE, Martino S, Sledge GW, Harris LN, Gralow JR, Dueck AC, Ketterling RP, Ingle JN, Lingle WL, Kaufman PA, Visscher DW, Jenkins RB. HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J Clin Oncol. 2010 Oct 01; 28: (28)4307-15.
    View PubMed
  171. Pockaj BA, Wasif N, Dueck AC, Wigle DA, Boughey JC, Degnim AC, Gray RJ, McLaughlin SA, Northfelt DW, Sticca RP, Jakub JW, Perez EA. Metastasectomy and surgical resection of the primary tumor in patients with stage IV breast cancer: time for a second look? Ann Surg Oncol. 2010 Sep; 17: (9)2419-26.
    View PubMed
  172. Bryce AH, Mattar B, Hillman SL, Adjei AA, Kugler JW, Rowland K, Wender DB, Soori G, Perez EA, Jett JR. Phase II trial of oral topotecan and intravenous carboplatin with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: A North Central Cancer Treatment Group Study. Am J Clin Oncol. 2010 Aug; 33(4):353-7.
    View PubMed
  173. Huang W, Reinholz M, Weidler J, Yolanda L, Paquet A, Whitcomb J, Lingle W, Jenkins RB, Chen B, Larson JS, Tan Y, Sherwood T, Bates M, Perez EA. Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assay. Am J Clin Pathol. 2010 Aug; 134(2):303-11.
    View PubMed
  174. Hillman SL, Mandrekar SJ, Bot B, DeMatteo RP, Perez EA, Ballman KV, Nelson H, Buckner JC, Sargent DJ. Evaluation of the value of attribution in the interpretation of adverse event data: a North Central Cancer Treatment Group and American College of Surgeons Oncology Group investigation. J Clin Oncol. 2010 Jun 20; 28: (18)3002-7.
    View PubMed
  175. Swain SM, Jeong JH, Geyer CE, Costantino JP, Pajon ER, Fehrenbacher L, Atkins JN, Polikoff J, Vogel VG, Erban JK, Rastogi P, Livingston RB, Perez EA, Mamounas EP, Land SR, Ganz PA, Wolmark N. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med. 2010 Jun 3; 362(22):2053-65.
    View PubMed
  176. Perez EA, Patel T, Moreno-Aspitia A. Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer. Breast Cancer Res Treat. 2010 Jun; 121(2):261-71. Epub 2010 Mar 13.
    View PubMed
  177. Saurel CA, Patel TA, Perez EA. Changes to adjuvant systemic therapy in breast cancer: a decade in review. Clin Breast Cancer. 2010 Jun; 10: (3)196-208.
    View PubMed
  178. Palmieri FM, Myatt CV, Perez EA. Adjuvant trastuzumab for HER2-positive early breast cancer. Clin J Oncol Nurs. 2010 Jun; 14(3):326-36.
    View PubMed
  179. Partridge AH, Archer L, Kornblith AB, Gralow J, Grenier D, Perez E, Wolff AC, Wang X, Kastrissios H, Berry D, Hudis C, Winer E, Muss H. Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104. J Clin Oncol. 2010 May 10; 28(14):2418-22. Epub 2010 Apr 05.
    View PubMed
  180. Ingle JN, Buzdar AU, Schaid DJ, Goetz MP, Batzler A, Robson ME, Northfelt DW, Olson JE, Perez EA, Desta Z, Weintraub RA, Williard CV, Flockhart DA, Weinshilboum RM. Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer. Cancer Res. 2010 Apr 15; 70: (8)3278-86.
    View PubMed
  181. Hines SL, Sloan JA, Atherton PJ, Perez EA, Dakhil SR, Johnson DB, Reddy PS, Dalton RJ, Mattar BI, Loprinzi CL. Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy. Breast. 2010 Apr; 19: (2)92-6.
    View PubMed
  182. Sparano JA, Pisano ED, White JR, Hunt KK, Mamounas EP, Perez EA, Hortobagyi GN, Gralow JR, Comis RL. Recommendations for research priorities in breast cancer by the coalition of cancer cooperative groups scientific leadership council: imaging and local therapy. Breast Cancer Res Treat. 2010 Apr; 120(2):273-84. Epub 2009 Dec 19.
    View PubMed
  183. Perez EA, Moreno-Aspitia A, Aubrey Thompson E, Andorfer CA. Adjuvant therapy of triple negative breast cancer. Breast Cancer Res Treat. 2010 Apr; 120: (2)285-91.
    View PubMed
  184. Tan WW, Hillman DW, Salim M, Northfelt DW, Anderson DM, Stella PJ, Niedringhaus R, Bernath AM, Gamini SS, Palmieri F, Perez EA. N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial. Ann Oncol. 2010 Mar; 21: (3)493-7.
    View PubMed
  185. Bernard JR, Vallow LA, DePeri ER, McNeil RB, Feigel DG, Amar S, Buskirk SJ, Perez EA. In newly diagnosed breast cancer, screening MRI of the contralateral breast detects mammographically occult cancer, even in elderly women: the mayo clinic in Florida experience. Breast J. 2010 Mar-Apr; 16(2):118-26. Epub 2010 Jan 29.
    View PubMed
  186. Perez EA, Hillman DW, Dentchev T, Le-Lindqwister NA, Geeraerts LH, Fitch TR, Liu H, Graham DL, Kahanic SP, Gross HM, Patel TA, Palmieri FM, Dueck AC. North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer. Ann Oncol. 2010 Feb; 21: (2)269-74.
    View PubMed
  187. Moulder S, Li H, Wang M, Gradishar WJ, Perez EA, Sparano JA, Pins M, Yang X, Sledge GW. A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial. Breast Cancer Res Treat. 2010 Feb; 119(3):663-71.
    View PubMed
  188. Shah SS, Ketterling RP, Goetz MP, Ingle JN, Reynolds CA, Perez EA, Chen B. Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer. Hum Pathol. 2010 Jan; 41(1):103-6. Epub 2009 Sep 16
    View PubMed
  189. Slovak ML, Bedell V, Lew D, Albain KS, Ellis GK, Livingston RB, Martino S, Perez EA, Hortobagyi GN, Sher D, Stock W. Screening for clonal hematopoiesis as a predictive marker for development of therapy-related myeloid neoplasia (t-MN) following neoadjuvant therapy for breast cancer: a Southwest Oncology Group study (S0012). Breast Cancer Res Treat. 2010 Jan; 119(2):391-8.
    View PubMed
  190. Burnell M, Levine MN, Chapman JA, Bramwell V, Gelmon K, Walley B, Vandenberg T, Chalchal H, Albain KS, Perez EA, Rugo H, Pritchard K, O'Brien P, Shepherd LE. Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer. J Clin Oncol. 2010 Jan 1; 28(1):77-82. Epub 2009 Nov 09.
    View PubMed
  191. Amar S, McCullough AE, Tan W, Geiger XJ, Boughey JC, McNeil RB, Coppola KE, McLaughlin SA, Palmieri FM, Perez EA. Prognosis and outcome of small (<=1 cm), node-negative breast cancer on the basis of hormonal and HER-2 status. Oncologist. 2010; 15(10):1043-9. Epub 2010 Oct 07.
    View PubMed
  192. Wagner L, Wang M, Miller KD, Davidson NE, Gralow JR, Dickler M, Cobleigh M, Perez EA, Soori GS. A Randomized Phase III Trial of Paclitaxel versus Paclitaxel plus Bevacizumab (rhuMAb QOL for VEGF) as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer: A Trial Coordinated by the Eastern Cooperative Oncology Group (E2100) Cancer. 2010.
    View PubMed
  193. Patel TA, Colon-Otero G, Bueno Hume, Copland JA, Perez EA. Breast cancer in Latinas: gene expression, differential response to treatments, and differential toxicities in Latinas compared with other population groups. Oncologist. 2010; 15(5):466-75. Epub 2010 Apr 28.
    View PubMed
  194. Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, Baehner FL, Davidson NE, Sledge GW, Winer EP, Hudis C, Ingle JN, Perez EA, Pritchard KI, Shepherd L, Gralow JR, Yoshizawa C, Allred DC, Osborne CK, Hayes DF, Breast Cancer Intergroup of North America. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010 Jan; 11(1):55-65. Epub 2009 Dec 10
    View PubMed
  195. Sparano JA, Goldstein LJ, Childs BH, Shak S, Brassard D, Badve S, Baehner FL, Bugarini R, Rowley S, Perez E, Shulman LN, Martino S, Davidson NE, Sledge GW, Gray R. Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer. Clin Cancer Res. 2009 Dec 15; 15(24):7693-700.
    View PubMed
  196. Asmann YW, Klee EW, Thompson EA, Perez EA, Middha S, Oberg AL, Therneau TM, Smith DI, Poland GA, Wieben ED, Kocher JP. 3' tag digital gene expression profiling of human brain and universal reference RNA using Illumina Genome Analyzer. BMC Genomics. 2009 Nov 16; 10:531.
    View PubMed
  197. Roy V, Perez EA. Beyond trastuzumab: small molecule tyrosine kinase inhibitors in HER-2-positive breast cancer. Oncologist. 2009 Nov; 14(11):1061-9. Epub 2009 Nov 03.
    View PubMed
  198. Hines SL, Mincey B, Dentchev T, Sloan JA, Perez EA, Johnson DB, Schaefer PL, Alberts S, Liu H, Kahanic S, Mazurczak MA, Nikcevich DA, Loprinzi CL. Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC. Breast Cancer Res Treat. 2009 Oct; 117: (3)603-9.
    View PubMed
  199. Grant CS, Ingle JN, Suman VJ, Dumesic DA, Wickerham DL, Gelber RD, Flynn PJ, Weir LM, Intra M, Jones WO, Perez EA, Hartmann LC. Menstrual cycle and surgical treatment of breast cancer: findings from the NCCTG N9431 study. J Clin Oncol. 2009 Aug 01; 27: (22)3620-6.
    View PubMed
  200. Perez EA. Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol Cancer Ther. 2009 Aug; 8(8):2086-95. Epub 2009 Aug 11.
    View PubMed
  201. Moreno-Aspitia A, Perez EA. Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends. Clin Ther. 2009 Aug; 31(8):1619-40.
    View PubMed
  202. Roy V, Perez EA. Biologic therapy of breast cancer: focus on co-inhibition of endocrine and angiogenesis pathways. Breast Cancer Res Treat. 2009 Jul; 116(1):31-8. Epub 2008 Dec 20.
    View PubMed
  203. Halyard MY, Pisansky TM, Dueck AC, Suman V, Pierce L, Solin L, Marks L, Davidson N, Martino S, Kaufman P, Kutteh L, Dakhil SR, Perez EA. Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. J Clin Oncol. 2009 Jun 01; 27: (16)2638-44.
    View PubMed
  204. Pockaj BA, Degnim AC, Boughey JC, Gray RJ, McLaughlin SA, Dueck AC, Perez EA, Halyard MY, Frost MH, Cheville AL, Sloan JA. Quality of life after breast cancer surgery: What have we learned and where should we go next? J Surg Oncol. 2009 Jun 1; 99(7):447-55.
    View PubMed
  205. Moreno-Aspitia A, Perez EA. Treatment options for breast cancer resistant to anthracycline and taxane. Mayo Clin Proc. 2009 Jun; 84: (6)533-45.
    View PubMed
  206. Sukov WR, Miller DV, Dueck AC, Tenner KS, Jenkins RB, Kaufman PA, Davidson NE, Dakhil SR, Martino S, Roy V, Perez EA. Benefit of adjuvant trastuzumab in breast cancer patients with focal HER2 amplified clones: Data from N9831 Intergroup Adjuvant Trial. J Clin Oncol. 2009 May 20; 27: (15_suppl)520.
    View PubMed
  207. Moreno-Aspitia A, Hillman DW, Dueck AC, Carney WP, Lingle WL, Tenner KS, Lafky JM, Reinholz MM, Kutteh LA, Perez EA. Baseline and recurrence levels of soluble HER2 (sHER2) in early-stage HER2-neu positive breast cancer (HER2+BC) from the NCCTG adjuvant Intergroup trial N9831. J Clin Oncol. 2009 May 20; 27: (15_suppl)539.
    View PubMed
  208. Robert NJ, Dieras V, Glaspy J, Brufsky A, Bondarenko I, Lipatov O, Perez E, Yardley D, Zhou X, Phan S. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). J Clin Oncol. 2009 May 20; 27: (15_suppl)1005.
    View PubMed
  209. Tan W, Allred J, Salim M, Flynn P, Kugler JW, Stella PJ, Wiesenfeld M, Bernath AM, Fitch TR, Perez EA. N0337: Phase II study of capecitabine in combination with vinorelbine and trastuzumab for the first or second treatment of HER2+ metastatic breast cancer. J Clin Oncol. 2009 May 20; 27: (15_suppl)1020.
    View PubMed
  210. Apsey H, Roy V, Pockaj B, Northfelt D, Sticca R, Nikcevich DA, Mattar B, Fitch T, Perez EA. Surgical practice patterns following NCCTG N0338 "Phase II trial of docetaxel and darboplatin administered every two weeks as induction therapy for stage II and stage III breast cancer." J Clin Oncol. 2009 May 20; 27: (15_suppl)623.
    View PubMed
  211. Bernard JR Jr, Vallow LA, McNeil RB, McLaughlin SA, Geiger XJ, Perez EA. In newly diagnosed breast cancer, is a contralateral prophylactic mastectomy necessary following a negative MRI? J Clin Oncol. 2009 May 20; 27: (15_suppl)627.
    View PubMed
  212. Reinholz MM, Kitzmann KA, Hobday TJ, Northfelt DW, LaPlant B, Allred JB, Dueck AC, Stella PJ, Lingle WL, Perez EA. Cytokeratin-19 (CK19) and mammaglobin (MGB1) gene expression in circulating tumor cells (CTCs) from metastatic breast cancer patients enrolled in the NCCTG trials, N0436 and N0437. J Clin Oncol. 2009 May 20; 27: (15_suppl)11095.
    View PubMed
  213. Baselga J, Gianni L, Gradishar WJ, Hudis C, Perez EA, Piccart-Gebhart M, Schwartzberg LS, Sledge G, Fleming TR. Phase IIb double-blind, randomized, placebo-controlled trials for the efficacy and safety of sorafenib in patients (pts) with metastatic or locally advanced breast cancer (BC): Review of the Trials to Investigate the Effects of Sorafenib in BC (TIES) program. J Clin Oncol. 2009 May 20; 27: (15_suppl)e12000.
    View PubMed
  214. McCullough A, Dueck A, Chen B, Reinholz M, Wiktor A, Lingle W, Jenkins R, Perez E. HER-2 central confirmatory testing using ASCO/CAP guidelines for trastuzumab/lapatinib trial MCCR RC0639. J Clin Oncol. 2009 May 20; 27: (15_suppl)e11527.
    View PubMed
  215. Muss HB, Berry DA, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB, Partridge AH, Dressler LG, Cohen HJ, Becker HP, Kartcheske PA, Wheeler JD, Perez EA, Wolff AC, Gralow JR, Burstein HJ, Mahmood AA, Magrinat G, Parker BA, Hart RD, Grenier D, Norton L, Hudis CA, Winer EP, CALGB Investigators. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med. 2009 May 14; 360(20):2055-65.
    View PubMed
  216. Brufsky AM, Bosserman LD, Caradonna RR, Haley BB, Jones CM, Moore HC, Jin L, Warsi GM, Ericson SG, Perez EA. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer. 2009 May; 9(2):77-85.
    View PubMed
  217. Amar S, Roy V, Perez EA. Treatment of metastatic breast cancer: looking towards the future. Breast Cancer Res Treat. 2009 Apr; 114(3):413-22. Epub 2008 May 09.
    View PubMed
  218. Palmieri FM, DePeri ER, Mincey BA, Smith JA, Wen LK, Chewar DM, Abaya R, Colon-Otero G, Perez EA. Comprehensive diagnostic program for medically underserved women with abnormal breast screening evaluations in an urban population. Mayo Clin Proc. 2009 Apr; 84: (4)317-22.
    View PubMed
  219. Hines SL, Tan WW, Moreno-Aspitia A, Roy V, Vallow LA, McLaughlin SA, Perez EA. A Practical Clinical Approach to Adjuvant Therapy in Breast Cancer - An Update. US Oncol. 2009 Apr; 20:49-53.
  220. Yang P, Mandrekar SJ, Hillman SH, Allen Ziegler KL, Sun Z, Wampfler JA, Cunningham JM, Sloan JA, Adjei AA, Perez E, Jett JR. Evaluation of glutathione metabolic genes on outcomes in advanced non-small cell lung cancer patients after initial treatment with platinum-based chemotherapy: an NCCTG-97-24-51 based study. J Thorac Oncol. 2009 Apr; 4: (4)479-85.
    View PubMed
  221. Hines SL, Mincey BA, Sloan JA, Thomas SP, Chottiner E, Loprinzi CL, Carlson MD, Atherton PJ, Salim M, Perez EA. Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer. J Clin Oncol. 2009 Mar 01; 27: (7)1047-53.
    View PubMed
  222. Perez EA. Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer. Breast Cancer Res Treat. 2009 Mar; 114(2):195-201. Epub 2008 Apr 29.
    View PubMed
  223. Reinholz MM, Bruzek AK, Visscher DW, Lingle WL, Schroeder MJ, Perez EA, Jenkins RB. Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response. Lancet Oncol. 2009 Mar; 10 (3):267-77
    View PubMed
  224. Moreno-Aspitia A, Morton RF, Hillman DW, Lingle WL, Rowland KM Jr, Wiesenfeld M, Flynn PJ, Fitch TR, Perez EA. Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. J Clin Oncol. 2009 Jan 01; 27: (1)11-5.
    View PubMed
  225. Perez EA, Palmieri FM, Brock SM. Trastuzumab. Cancer Treat Res. 2009; 151:181-96.
    View PubMed
  226. Halyard M, Pisansky T, Dueck A, Pierce L, Solin L, Marks L, Davidson N, Martino S, Kaufman P, Kutteh L, Dakhil S, Perez E. Radiotherapy and Adjuvant Trastuzumab in Stage I-IIA Breast Cancer: Tolerability and Adverse Event Data From the North Central Cancer Treatment Group Phase I Trial N9831. J Clin Oncol. 2009; 27:2638-44.
    View PubMed
  227. Mincey B, Dentchev T, Sloan J, Hines S, Perez E, Johnson D, Schaefer P, Alberts S, Liu H, Wender D, Mazurczak M, Nikcevich D, Loprinzi C. Immediate vs. Delayed Zoledronic Acid for Prevention of Bone Loss in Postmenopausal Women with Breast Cancer Starting Letrozole After Tamoxifen - N03CC. Breast Cancer Res Treat. 2009; 117:603-9.
    View PubMed
  228. Muss H, Berry D, Cirrincione C, Theodoulou M, Mauer A, Kornblith A, Partridge A, Dressler L, Cohen H, Becker H, Norton L, Kartcheske P, Wheeler J, Perez E, Wolff A, Gralow J, Mahmood A, Parker B, Hudis C, Winer E. Adjuvant Chemotherapy with Standard Regimens in Superior to Capecitabine in Older Women with Early Stage Breast Cancer J Clin Oncol. 2009.
    View PubMed
  229. Moulder S, Li H, Wang M, Gradishar W, Perez E, Sparano J, Pins M, Yang X, Sledge G. A Phase II Trial of Trastuzumab Plus Weekly Ixabepilone and Carboplatin in Patients With HER2-Positive Metastatic Breast Cancer: An Eastern Cooperative Oncology Group Trial. Breast Cancer Research and Treatment. 2009.
    View PubMed
  230. Soto E, Yanagisawa M, Marlow LA, Copland JA, Perez EA, Anastasiadis PZ. p120 catenin induces opposing effects on tumor cell growth depending on E-cadherin expression. J Cell Biol. 2008 Nov 17; 183: (4)737-49.
    View PubMed
  231. Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, Flockhart DA, Hancock B, Davidson N, Gralow J, Dickler M, Perez EA, Cobleigh M, Shenkier T, Edgerton S, Miller KD, Ecog 2100. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol. 2008 Oct 1; 26(28):4672-8.
    View PubMed
  232. Grothey A, Adjei AA, Alberts SR, Perez EA, Jaeckle KA, Loprinzi CL, Sargent DJ, Sloan JA, Buckner JC, North Central. North Central Cancer Treatment Group--achievements and perspectives. Semin Oncol. 2008 Oct; 35(5):530-44.
    View PubMed
  233. Goetz MP, Suman VJ, Couch FJ, Ames MM, Rae JM, Erlander MG, Ma XJ, Sgroi DC, Reynolds CA, Lingle WL, Weinshilboum RM, Flockhart DA, Desta Z, Perez EA, Ingle JN. Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance. Clin Cancer Res. 2008 Sep 15; 14: (18)5864-8.
    View PubMed
  234. Hines SL, Vallow LA, Tan WW, McNeil RB, Perez EA, Jain A. Clinical outcomes after a diagnosis of brain metastases in patients with estrogen- and/or human epidermal growth factor receptor 2-positive versus triple-negative breast cancer. Ann Oncol. 2008 Sep; 19: (9)1561-5.
    View PubMed
  235. Goldstein LJ, O'Neill A, Sparano JA, Perez EA, Shulman LN, Martino S, Davidson NE. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. J Clin Oncol. 2008 Sep 1; 26(25):4092-9. Epub 2008 Aug 04.
    View PubMed
  236. Goldstein LJ, Gray R, Badve S, Childs BH, Yoshizawa C, Rowley S, Shak S, Baehner FL, Ravdin PM, Davidson NE, Sledge GW, Perez EA, Shulman LN, Martino S, Sparano JA. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol. 2008 Sep 1; 26(25):4063-71. Epub 2008 Aug 04.
    View PubMed
  237. Perez EA, Baweja M. HER2-positive breast cancer: current treatment strategies. Cancer Invest. 2008 Jul; 26(6):545-52.
    View PubMed
  238. Regan MM, Pagani O, Walley B, Torrisi R, Perez EA, Francis P, Fleming GF, Price KN, Thurlimann B, Maibach R, Castiglione-Gertsch M, Coates AS, Goldhirsch A, Gelber RD, SOFT/TEXT/PERCHE Steering, International Breast. Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? Ann Oncol. 2008 Jul; 19(7):1231-41. Epub 2008 Mar 5.
    View PubMed
  239. Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E, Ewer MS. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc. 2008 Jun; 83(6):679-86.
    View PubMed
  240. Badve SS, Baehner FL, Gray RP, Childs BH, Maddala T, Liu ML, Rowley SC, Shak S, Perez EA, Shulman LJ, Martino S, Davidson NE, Sledge GW, Goldstein LJ, Sparano JA. Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol. 2008 May 20; 26(15):2473-81.
    View PubMed
  241. Roy V, Pockaj BA, Northfelt DW, Allred JB, Liu H, Nikcevich DA, Mattar BI, Perez EA. N0338 phase II trial of docetaxel and carboplatin administered every two weeks as induction therapy for stage II or III breast cancer. J Clin Oncol. 2008 May 20; 26: (15_suppl)563.
    View PubMed
  242. Mincey BA, Dentchev T, Sloan JA, Hines SL, Perez EA, Johnson DB, Schaefer PL, Liu H, Kahanic SP, Loprinzi CL. N03CC-a randomized, controlled, open-label trial of upfront vs. delayed zoledronic acid for prevention of bone loss in postmenopausal (PM) women with primary breast cancer (PBC) starting letrozole after tamoxifen. J Clin Oncol. 2008 May 20; 26: (15_suppl)564.
    View PubMed
  243. Bernard JR Jr, Vallow LA, DePeri ER, Feigel DG, Amar S, Buskirk SJ, Perez EA. Mammographically occult contralateral breast carcinoma detected by magnetic resonance imaging in the elderly. J Clin Oncol. 2008 May 20; 26: (15_suppl)500.
    View PubMed
  244. Hines SL, Mincey BA, Sloan JA, Thomas SP, Chottiner EG, Loprinzi CL, Atherton PJ, Carlson MD, Salim M, Perez EA. N02C1: A phase III randomized, placebo-controlled, double-blind trial of risedronate for prevention of bone loss in premenopausal women undergoing adjuvant chemotherapy for breast cancer (BC). J Clin Oncol. 2008 May 20; 26: (15_suppl)525.
    View PubMed
  245. Moreno-Aspitia A, Dueck AC, Lingle WL, Kutteh L, Tenner K, Davidson NE, Martino S, Kaufman P, Carney WP, Perez EA. Serum HER2 (sHER2) levels in early-stage HER2 neu (+) breast cancer (HER2+BC): Results from the NCCTG adjuvant Intergroup trial N9831. J Clin Oncol. 2008 May 20; 26: (15_suppl)529.
    View PubMed
  246. Miller KD, O'Neill A, Perez EA, Seidman AD, Sledge GW. Phase II feasibility trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node-positive breast cancer: A trial of the Eastern Cooperative Oncology Group (E2104). J Clin Oncol. 2008 May 20; 26: (15_suppl)520.
    View PubMed
  247. Dueck AC, Atherton PJ, Liu H, Hines SL, Loprinzi CL, Perez EA, Tan AD, Burger K, Zhao X, Diekmann B, Sloan JA. Endpoint comparison for osteoporosis assessment in cancer control studies (N02C1 and N03CC). J Clin Oncol. 2008 May 20; 26: (15_suppl)6627.
    View PubMed
  248. Partridge AH, Archer LE, Kornblith AB, Gralow JR, Grenier D, Perez EA, Wolff AC, Hudis CA, Winer EP, Muss H, North American Breast Intergroup. CALGB 60104: Adherence with adjuvant capecitabine among women age 65 and older with early stage breast cancer treated on CALGB 49907. J Clin Oncol. 2008 May 20; 26: (15_suppl)6542.
    View PubMed
  249. Goetz MP, Moyer AM, Weinshilboum RM, Suman VA, Hebbring SJ, Ames MM, Berg JC, Reynolds C, Perez EA, Ingle JN. Role of SULT1A1 copy number in tamoxifen treated breast cancer: Findings from the North Central Cancer Treatment Group (NCCTG) adjuvant trial 89-30-52. J Clin Oncol. 2008 May 20; 26: (15_suppl)22041.
    View PubMed
  250. Reinholz MM, Dueck AC, Lingle WL, Allen Ziegler KL, Wiktor AE, Paik S, Jenkins RB, Perez EA. The concordance between NCCTG's and NSABP's C-myc FISH assays. J Clin Oncol. 2008 May 20; 26: (15_suppl)22110.
    View PubMed
  251. Northfelt DW, Allred JB, Liu H, Hobday TJ, Rodacker MW, Lyss AP, Fitch TR, Perez EA. Phase II trial of paclitaxel polyglumex (PPX) with capecitabine (C) for metastatic breast cancer (MBC). J Clin Oncol. 2008 May 20; 26: (15_suppl)1063.
    View PubMed
  252. Hobday TJ, Stella PJ, Fitch TR, Jaslowski A, LaPlant B, Ames MM, Goetz MP, Perez EA. N0436: A phase II trial of irinotecan plus cetuximab in patients with metastatic breast cancer and prior anthracycline and/or taxane-containing therapy. J Clin Oncol. 2008 May 20; 26: (15_suppl)1081.
    View PubMed
  253. Klencke BJ, Bhattacharya S, Samant MK, Gralow JR, Dickler MN, Cobleigh MA, Perez EA, Shenkier TN, Davidson NE, Miller KD. Independent review of E2100 progression-free survival (PFS) with the addition of bevacizumab (B) to paclitaxel (P) as initial chemotherapy for metastatic breast cancer (MBC). J Clin Oncol. 2008 May 20; 26: (15_suppl)1036.
    View PubMed
  254. Ingle JN, Tu D, Pater JL, Muss HB, Martino S, Robert NJ, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Goss PE. Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. Ann Oncol. 2008 May; 19: (5)877-82.
    View PubMed
  255. Johnson EA, Marks RS, Mandrekar SJ, Hillman SL, Hauge MD, Bauman MD, Wos EJ, Moore DF, Kugler JW, Windschitl HE, Graham DL, Bernath AM Jr, Fitch TR, Soori GS, Jett JR, Adjei AA, Perez EA. Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51). Lung Cancer. 2008 May; 60(2):200-7. Epub 2007 Nov 28.
    View PubMed
  256. Amar S, Moreno-Aspitia A, Perez EA. Issues and controversies in the treatment of HER2 positive metastatic breast cancer. Breast Cancer Res Treat. 2008 May; 109(1):1-7. Epub 2007 Jul 26
    View PubMed
  257. Brufsky A, Bundred N, Coleman R, Lambert-Falls R, Mena R, Hadji P, Jin L, Schenk N, Ericson S, Perez EA, Z-FAST and ZO-FAST Study Groups. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist. 2008 May; 13(5):503-14.
    View PubMed
  258. Goss PE, Ingle JN, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Tu D. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol. 2008 Apr 20; 26(12):1948-55. Epub 2008 Mar 10.
    View PubMed
  259. Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW, Wood WC, Davidson NE. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008 Apr 17; 358(16):1663-71.
    View PubMed
  260. Perez EA, Suman VJ, Davidson NE, Sledge GW, Kaufman PA, Hudis CA, Martino S, Gralow JR, Dakhil SR, Ingle JN, Winer EP, Gelmon KA, Gersh BJ, Jaffe AS, Rodeheffer RJ. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol. 2008 Mar 10; 26: (8)1231-8.
    View PubMed
  261. Perez EA. Cardiac toxicity of ErbB2-targeted therapies: what do we know? Clin Breast Cancer. 2008 Mar; 8 Suppl 3:S114-20
    View PubMed
  262. Gralow J, Rugo H, Gradishar W, O'Shaughnessy JA, Jahanzeb M, Perez E, Tripathy D. Novel taxane formulations in the treatment of breast cancer: a thought leader discussion and consensus roundtable. Clin Breast Cancer. 2008 Feb; 8(1):33-7.
    View PubMed
  263. Perez EA. Modulating drug resistance in metastatic breast cancer. Community Oncol. 2008; 5(4 SUPPL. 3):2-9.
    View PubMed
  264. Colon-Otero G, King S, Smith V, Bieber C, Crook J, Solberg LA, Shannon R, Perez EA. Increased incidence of loco-regional recurrences among african american women with terminal stage breast cancer. Clin Med Oncol. 2008; 2:547-50. Epub 2008 Nov 03.
    View PubMed
  265. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007 Dec 27; 357(26):2666-76.
    View PubMed
  266. Gabrilove JL, Perez EA, Tomita DK, Rossi G, Cleeland CS. Assessing symptom burden using the M. D. Anderson symptom inventory in patients with chemotherapy-induced anemia: results of a multicenter, open-label study (SURPASS) of patients treated with darbepoetin-alpha at a dose of 200 microg every 2 weeks. Cancer. 2007 Oct 1; 110(7):1629-40.
    View PubMed
  267. Pruthi S, Boughey JC, Brandt KR, Degnim AC, Dy GK, Goetz MP, Perez EA, Reynolds CA, Schomberg PJ, Ingle JN. A multidisciplinary approach to the management of breast cancer, part 2: therapeutic considerations. Mayo Clin Proc. 2007 Sep; 82(9):1131-40.
    View PubMed
  268. Perez EA. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer. Ann Oncol. 2007 Sep; 18 Suppl 8:viii26-35.
    View PubMed
  269. Perez EA, Lerzo G, Pivot X, Thomas E, Vahdat L, Bosserman L, Viens P, Cai C, Mullaney B, Peck R, Hortobagyi GN. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2007 Aug 10; 25(23):3407-14. Epub 2007 Jul 02.
    View PubMed
  270. Garrison LP, Lubeck D, Lalla D, Paton V, Dueck A, Perez EA. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. Cancer. 2007 Aug 1; 110(3):489-98.
    View PubMed
  271. Amar S, Roy V, Perez EA. Letrozole: present and future role in the treatment of breast cancer. Expert Opin Pharmacother. 2007 Aug; 8(12):1965-75.
    View PubMed
  272. Pruthi S, Brandt KR, Degnim AC, Goetz MP, Perez EA, Reynolds CA, Schomberg PJ, Dy GK, Ingle JN. A multidisciplinary approach to the management of breast cancer, part 1: prevention and diagnosis. Mayo Clin Proc. 2007 Aug; 82(8):999-1012.
    View PubMed
  273. Perez EA. Novel enhanced delivery taxanes: an update. Semin Oncol. 2007 Jun; 34(3):suppl 1-5.
    View PubMed
  274. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL, National Cancer Institute of Canada Clinical Trials Group MA.17. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. J Clin Oncol. 2007 May 20; 25(15):2006-11. Epub 2007 Apr 23.
    View PubMed
  275. Halyard MY, Jatoi A, Sloan JA, Bearden JD, Vora SA, Atherton PJ, Perez EA, Soori G, Zalduendo AC, Zhu A, Stella PJ, Loprinzi CL. Does zinc sulfate prevent therapy-induced taste alterations in head and neck cancer patients? Results of phase III double-blind, placebo-controlled trial from the North Central Cancer Treatment Group (N01C4). Int J Radiat Oncol Biol Phys. 2007 Apr 1; 67(5):1318-22.
    View PubMed
  276. Brufsky A, Harker WG, Beck JT, Carroll R, Tan-Chiu E, Seidler C, Hohneker J, Lacerna L, Petrone S, Perez EA. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol. 2007 Mar 1; 25(7):829-36. Epub 2006 Dec 11.
    View PubMed
  277. Hines SL, Tan WW, Yasrebi M, DePeri ER, Perez EA. The role of mammography in male patients with breast symptoms. Mayo Clin Proc. 2007 Mar; 82: (3)297-300.
    View PubMed
  278. Palmieri FM, Perez EA. Managing high-risk breast cancer. Semin Oncol Nurs. 2007 Feb; 23: (1)29-36.
    View PubMed
  279. Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Weinshilboum RM, Fritcher EG, Nibbe AM, Desta Z, Nguyen A, Flockhart DA, Perez EA, Ingle JN. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2007 Jan; 101: (1)113-21.
    View PubMed
  280. Perez EA. Safety of aromatase inhibitors in the adjuvant setting. Breast Cancer Res Treat. 2007; 105 Suppl 1:75-89.
    View PubMed
  281. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF, American Society of Clinical Oncology, College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007 Jan 1; 25(1):118-45. Epub 2006 Dec 11.
    View PubMed
  282. Perez E, Morton R, Hillman D, Moreno-Aspitio A, Lingle W, Rowland K, Wiesenfeld M, Flynn P, Fitch T. Phase II Trial of Sorafenib as Single Oral Agent in Patients With Metastatic Breast Cancer Previously Exposed to Anthracyclines and/or Taxanes, N0336 J Clin Oncol. 2007.
    View PubMed
  283. Perez EA. Appraising adjuvant aromatase inhibitor therapy. Oncologist. 2006 Nov-Dec; 11: (10)1058-69.
    View PubMed
  284. Ingle JN, Tu D, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Goss PE. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Res Treat. 2006 Oct; 99(3):295-300. Epub 2006 Mar 16.
    View PubMed
  285. Perez EA. The balance between risks and benefits: Long-term use of aromatase inhibitors. European Journal of Cancer Supplement 1990. 2006 Sep; 4(9):16-25.
    View PubMed
  286. Perez EA, Weilbaecher K. Aromatase inhibitors and bone loss. Oncology (Williston Park). 2006 Aug; 20: (9)1029-39; discussion 1039-40, 104.
    View PubMed
  287. Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, Shenkier TN, Tozer RG, Palmer MJ, Shepherd LE, Liu S, Tu D, Goss PE. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol. 2006 Aug 1; 24(22):3629-35. Epub 2006 Jul 05.
    View PubMed
  288. Perez EA, Suman VJ, Davidson NE, Martino S, Kaufman PA, Lingle WL, Flynn PJ, Ingle JN, Visscher D, Jenkins RB. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol. 2006 Jul 1; 24(19):3032-8.
    View PubMed
  289. Ingle JN, Suman VJ, Mailliard JA, Kugler JW, Krook JE, Michalak JC, Pisansky TM, Wold LE, Donohue JH, Goetz MP, Perez EA. Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52. Breast Cancer Res Treat. 2006 Jul; 98(2):217-22. Epub 2006 Mar 15.
    View PubMed
  290. Thomas E, Perez EA, Mukhopadhyay P, Lerzo G, Pivot X, Bosserman LD, Mullaney B, Vahdat L, Hortobagyi GN. Phase II trial of ixabepilone in patients with metastatic breast cancer (MBC) who are resistant to an anthracycline, a taxane and capecitabine. J Clin Oncol. 2006 Jun 20; 24: (18_suppl)660.
    View PubMed
  291. Vallow LA, Packianathan S, Deperi ER, McDonough MD, Earle JD, Perez EA. Pre-operative breast magnetic resonance imaging (MRI) influences patient selection for partial breast irradiation. J Clin Oncol. 2006 Jun 20; 24: (18_suppl)604.
    View PubMed
  292. Halyard MY, Pisansky TM, Solin LJ, Marks LB, Pierce LJ, Dueck A, Perez EA. Adjuvant radiotherapy (RT) and trastuzumab in stage I-IIA breast cancer: Toxicity data from North Central Cancer Treatment Group Phase III trial N9831. J Clin Oncol. 2006 Jun 20; 24: (18_suppl)523.
    View PubMed
  293. Knox SK, Ingle JN, Suman VJ, Rae JM, Flockhart DA, Zeruesenay D, Ames MM, Visscher DW, Perez EA, Goetz MP. Cytochrome P450 2D6 status predicts breast cancer relapse in women receiving adjuvant tamoxifen (Tam). J Clin Oncol. 2006 Jun 20; 24: (18_suppl)504.
    View PubMed
  294. Mincey B, Duh M, Thomas S, Moyneur E, Marynchencko M, Boyce S, Perez E. Risk of cancer treatment-related osteoporosis and fractures among women with breast cancer receiving aromatase inhibitors. J Clin Oncol. 2006 Jun 20; 24: (18_suppl)557.
    View PubMed
  295. Moreno-Aspitia A, Hillman DW, Wiesenfeld M, Hobday TJ, Rowland KM, Northfelt DW, Tenner KS, Palmieri FM, Perez EA. BAY 43-9006 as single oral agent in patients with metastatic breast cancer previously exposed to anthracycline and/or taxane. J Clin Oncol. 2006 Jun 20; 24: (18_suppl)577.
    View PubMed
  296. Perez EA, Byrne JA, Hammond IW, Rafi R, Martin AM, Berger MS, Zaks TZ, Oliva CR, Roychowdhury DF, Stein SH. Results of an analysis of cardiac function in 2,812 patients treated with lapatinib. J Clin Oncol. 2006 Jun 20; 24: (18_suppl)583.
    View PubMed
  297. Garrison LP Jr, Perez EA, Dueck A, Lalla D, Paton V, Lubeck D. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2+ breast cancer. J Clin Oncol. 2006 Jun 20; 24: (18_suppl)6023.
    View PubMed
  298. Hillman SL, Mandrekar SJ, Bot BM, Perez EA, Kugler JW, Adjei AA, Buckner JC, Sargent DJ. Should attribution be considered when interpreting adverse event data: A North Central Cancer Treatment Group (NCCTG) evaluation of a phase III placebo controlled trial. J Clin Oncol. 2006 Jun 20; 24: (18_suppl)6006.
    View PubMed
  299. Ellis GK, Barlow WE, Russell CA, Royce ME, Perez EA, Livingston RB. SWOG 0012, a randomized phase III comparison of standard doxorubicin (A) and cyclophosphamide (C) followed by weekly paclitaxel (T) versus weekly doxorubicin and daily oral cyclophosphamide plus G-CSF (G) followed by weekly paclitaxel as neoadjuvant therapy for inflammatory and locally advanced breast cancer. J Clin Oncol. 2006 Jun 20; 24: (18_suppl)LBA537.
    View PubMed
  300. Yang P, Mandrekar SJ, Hillman SL, Allen KL, Sun Z, Wampfler J, Cunningham JM, Jett JR, Adjei AA, Perez EA. Evaluation of platinum-based chemotherapy, glutathione metabolic genes, and survival in advanced non small cell lung cancer: A NCCTG 97-24-51 based study. J Clin Oncol. 2006 Jun 20; 24: (18_suppl)13013.
    View PubMed
  301. Roy V, Perez EA. New therapies in the treatment of breast cancer. Semin Oncol. 2006 Jun; 33(3 Suppl 9):S3-8.
    View PubMed
  302. Mincey BA, Duh MS, Thomas SK, Moyneur E, Marynchencko M, Boyce SP, Mallett D, Perez EA. Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors. Clin Breast Cancer. 2006 Jun; 7(2):127-32.
    View PubMed
  303. Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein LJ, Martino S, Perez EA, Muss HB, Norton L, Hudis C, Winer EP. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA. 2006 Apr 12; 295(14):1658-67.
    View PubMed
  304. Goetz MP, Suman VJ, Ingle JN, Nibbe AM, Visscher DW, Reynolds CA, Lingle WL, Erlander M, Ma XJ, Sgroi DC, Perez EA, Couch FJ. A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen. Clin Cancer Res. 2006 Apr 01; 12: (7 Pt 1)2080-7.
    View PubMed
  305. Baweja M, Suman VJ, Fitch TR, Mailliard JA, Bernath A, Rowland KM, Alberts SR, Kaur JS, Perez EA, NCCTG. Phase II trial of oral vinorelbine for the treatment of metastatic breast cancer in patients > or = 65 years of age: an NCCTG study. Ann Oncol. 2006 Apr; 17: (4)623-9.
    View PubMed
  306. Carlson RW, Brown E, Burstein HJ, Gradishar WJ, Hudis CA, Loprinzi C, Mamounas EP, Perez EA, Pritchard K, Ravdin P, Recht A, Somlo G, Theriault RL, Winer EP, Wolff AC, National Comprehensive Cancer Network. NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. J Natl Compr Canc Netw. 2006 Mar; 4 Suppl 1:S1-26.
    View PubMed
  307. Ingle JN, Suman VJ, Rowland KM, Mirchandani D, Bernath AM, Camoriano JK, Fishkin PA, Nikcevich DA, Perez EA, North Central Cancer Treatment Group Trial N0032. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. J Clin Oncol. 2006 Mar 1; 24(7):1052-6.
    View PubMed
  308. Slamon DJ, Romond EH, Perez EA, CME Consultants Inc. Advances in adjuvant therapy for breast cancer. Clin Adv Hematol Oncol. 2006 Mar; 4(3 Suppl 7):suppl 1, 4-9; discussion suppl 10; quiz 2 p follow.
    View PubMed
  309. Ma CX, Steen P, Rowland KM, Niedringhaus RD, Fitch TR, Kugler JW, Hillman DW, Perez EA, Ingle JN, Adjei AA. A phase II trial of a combination of pemetrexed and gemcitabine in patients with metastatic breast cancer: an NCCTG study. Ann Oncol. 2006 Feb; 17: (2)226-31.
    View PubMed
  310. Roy V, Perez EA. Adjuvant docetaxel plus doxorubicin and cyclophosphamide increases survival compared with fluorouracil plus doxorubicin and cyclophosphamide in women with operable node-positive breast cancer. Cancer Treat Rev. 2006 Feb; 32(1):55-8. Epub 2006 Jan 19.
    View PubMed
  311. Wirk B, Perez E. Role of gemcitabine in breast cancer management: an update. Semin Oncol. 2006 Feb; 33(1 Suppl 2):S6-14.
    View PubMed
  312. Wirk B, Perez E. Role of Gemcitabine in Breast Cancer Management: An Update. Semin Oncol. 2006 Feb; 33 Suppl 2:6-14.
    View PubMed
  313. Baselga J, Perez EA, Pienkowski T, Bell R. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist. 2006; 11 Suppl 1:4-12.
    View PubMed
  314. Perez EA. Other significant research and future directions. Clinical Advances in Hematology and Oncology. 2006; 4(3 Suppl 7):8-9.
    View PubMed
  315. Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Flockhart DA, Desta Z, Perez EA, Ingle JN. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol. 2005 Dec 20; 23(36):9312-8.
    View PubMed
  316. Jatoi A, Hillman S, Stella P, Green E, Adjei A, Nair S, Perez E, Amin B, Schild SE, Castillo R, Jett JR, North Central Cancer Treatment Group. Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group. J Clin Oncol. 2005 Dec 20; 23(36):9113-9.
    View PubMed
  317. Perez EA, Suman VJ, Rowland KM, Ingle JN, Salim M, Loprinzi CL, Flynn PJ, Mailliard JA, Kardinal CG, Krook JE, Thrower AR, Visscher DW, Jenkins RB. Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer. 2005 Dec; 6(5):425-32.
    View PubMed
  318. Moreno-Aspitia A, Perez EA. Nanoparticle albumin-bound paclitaxel (ABI-007): a newer taxane alternative in breast cancer. Future Oncol. 2005 Dec; 1(6):755-62.
    View PubMed
  319. Perez E, Muss HB. Optimizing adjuvant chemotherapy in early-stage breast cancer. Oncology (Williston Park). 2005 Dec; 19(14):1759-67; discussion 1768, 1772-4, 1777-8.
    View PubMed
  320. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005 Oct 20; 353(16):1673-84.
    View PubMed
  321. Eniu A, Palmieri FM, Perez EA. Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer. Oncologist. 2005 Oct; 10(9):665-85.
    View PubMed
  322. Moreno-Aspitia A, Perez EA. North Central Cancer Treatment Group N0531: Phase II Trial of weekly albumin-bound paclitaxel (ABI-007; Abraxane) in combination with gemcitabine in patients with metastatic breast cancer. Clin Breast Cancer. 2005 Oct; 6(4):361-4.
    View PubMed
  323. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005 Sep 7; 97(17):1262-71.
    View PubMed
  324. Perez EA, Hillman DW, Fishkin PA, Krook JE, Tan WW, Kuriakose PA, Alberts SR, Dakhil SR. Phase II trial of dolastatin-10 in patients with advanced breast cancer. Invest New Drugs. 2005 Jun; 23 (3):257-61
    View PubMed
  325. Johnson EA, Marks RS, Mandrekar S, Hillman S, Mailliard J, Dentchev T, Reuter N, Jett J, Perez EA. A phase III randomized placebo controlled NCCTG trial of carboxyaminoimidazole (CAI) in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2005 Jun; 23: (16_suppl)7054.
    View PubMed
  326. Baweja M, Suman V, Fitch TR, Mailliard JA, Bernath A, Rowland KM, Alberts SR, Kaur JS, Perez EA. Phase II trial of oral vinorelbine for treatment of metastatic breast cancer in women 65 years and older: N003A. J Clin Oncol. 2005 Jun; 23: (16_suppl)740.
    View PubMed
  327. Graham DL, Hillman DW, Hobday TJ, Rousey SR, Nair SG, Soori GS, Sabagh TM, Perez EA. N0234: Phase II study of erlotinib (OSI-774) plus gemcitabine as first-or second-line therapy for metastatic breast cancer (MBC). J Clin Oncol. 2005 Jun; 23: (16_suppl)644.
    View PubMed
  328. Boyce SP, Mincey BA, Duh MS, Marynchenko M, Raut MK, Brandman J, Perez EA. Risk of osteoporosis/osteopenia among women with breast cancer receiving anti-cancer therapy (ACT). J Clin Oncol. 2005 Jun; 23: (16_suppl)665.
    View PubMed
  329. Goldstein LJ, O'Neill A, Sparano J, Perez E, Shulman L, Martino S, Davidson N. E2197: Phase III AT (doxorubicin/docetaxel) vs. AC (doxorubicin/cyclophosphamide) in the adjuvant treatment of node positive and high risk node negative breast cancer. J Clin Oncol. 2005 Jun; 23: (16_suppl)512.
    View PubMed
  330. Perez EA, Suman VJ, Davidson NE, Kaufman PA, Martino S, Dakhil SR, Ingle JN, Rodeheffer RJ, Gersh BJ, Hillman DW, Jaffe AS. Interim cardiac safety analysis of NCCTG N9831 Intergroup adjuvant trastuzumab trial. J Clin Oncol. 2005 Jun; 23: (16_suppl)556.
    View PubMed
  331. Wasan KM, Goss PE, Pritchard PH, Shepherd L, Palmer MJ, Liu S, Tu D, Ingle JN, Heath M, Deangelis D, Perez EA. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Ann Oncol. 2005 May; 16(5):707-15. Epub 2005 Apr 07.
    View PubMed
  332. Lafky JM, Baron AT, Cora EM, Hillman DW, Suman VJ, Perez EA, Ingle JN, Maihle NJ. Serum soluble epidermal growth factor receptor concentrations decrease in postmenopausal metastatic breast cancer patients treated with letrozole. Cancer Res. 2005 Apr 15; 65(8):3059-62.
    View PubMed
  333. Burch PA, Mailliard JA, Hillman DW, Perez EA, Krook JE, Rowland KM, Veeder MH, Cannon MW, Ingle JN. Phase II study of gemcitabine plus cisplatin in patients with metastatic breast cancer: a North Central Cancer Treatment Group Trial. Am J Clin Oncol. 2005 Apr; 28(2):195-200.
    View PubMed
  334. Hobday TJ, Perez EA. Molecularly targeted therapies for breast cancer. Cancer Control. 2005 Apr; 12(2):73-81.
    View PubMed
  335. Muss HB, Von Roenn J, Damon LE, Deangelis LM, Flaherty LE, Harari PM, Kelly K, Kosty MP, Loscalzo MJ, Mennel R, Mitchell BS, Mortimer JE, Muggia F, Perez EA, Pisters PW, Saltz L, Schapira L, Sparano J, American Society of Clinical Oncology. ACCO: ASCO core curriculum outline. J Clin Oncol. 2005 Mar 20; 23(9):2049-77. Epub 2005 Feb 22.
    View PubMed
  336. Perez EA, Suman VJ, Fitch TR, Mailliard JA, Ingle JN, Cole JT, Veeder MH, Flynn PJ, Walsh DJ, Addo FK. A phase II trial of docetaxel and carboplatin as first-line chemotherapy for metastatic breast cancer: NCCTG study N9932. Oncology. 2005; 69(2):117-21. Epub 2005 Aug 23.
    View PubMed
  337. Perez EA. Trastuzumab as part of adjuvant therapy for patients with HER2-positive breast cancer. The Amer J of Oncol Review. 2005; 4(11 Suppl 15):11-3.
    View PubMed
  338. McDonough RF, Perez EA. Advances in Systemic Therapy for Breast Cancer. North East Florida Medical Journal Fall. 2005:39-42.
    View PubMed
  339. Amin B, Hillman S, Nikcevich D, Dakhil S, Mailliard J, Fitch T, Bernath, Jr. A, Jett J, Perez E. Randomized Phase II Study of Docetaxel and Gemcitabine for Stage IIIB/IV Non-Small Cell Lung Cancer: An NCCTG study Lung Cancer. 2005.
    View PubMed
  340. Perez E. Addressing the risk of late breast cancer recurrence: new data and recommendations for extended adjuvant therapy The Breast. 2005.
    View PubMed
  341. Perez EA, Pusztai L, Van de Vijver M. Improving patient care through molecular diagnostics. Semin Oncol. 2004 Oct; 31(5 Suppl 10):14-20.
    View PubMed
  342. Baselga J, Gianni L, Geyer C, Perez EA, Riva A, Jackisch C. Future options with trastuzumab for primary systemic and adjuvant therapy. Semin Oncol. 2004 Oct; 31(5 Suppl 10):51-7.
    View PubMed
  343. Tack DK, Palmieri FM, Perez EA. Anthracycline vs nonanthracycline adjuvant therapy for breast cancer. Oncology (Williston Park). 2004 Oct; 18(11):1367-76; discussion 1378, 1381.
    View PubMed
  344. Perez EA, Suman VJ, Davidson NE, Kaufman PA, Martino S, Dakhil SR, Ingle JN, Rodeheffer RJ, Gersh BJ, Jaffe AS. Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. J Clin Oncol. 2004 Sep 15; 22(18):3700-4.
    View PubMed
  345. Perez EA, Hillman DW, Mailliard JA, Ingle JN, Ryan JM, Fitch TR, Rowland KM, Kardinal CG, Krook JE, Kugler JW, Dakhil SR. Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. J Clin Oncol. 2004 Jul 15; 22: (14)2849-55.
    View PubMed
  346. Miller DV, Jenkins RB, Lingle WL, Davidson NE, Kaufman PA, Martino S, Dakhil SR, Perez EA. Focal HER2/neu amplified clones partially account for discordance between immunohistochemistry and fluorescence in-situ hybridization results: data from NCCTG N9831 Intergroup Adjuvant Trial. J Clin Oncol. 2004 Jul 15; 22: (14_suppl)568.
    View PubMed
  347. Perez EA, Suman VJ, Davidson NE, Martino S, Kaufman PA, Lingle WL, Flynn PJ, Ingle JN, Visscher D, Jenkins RB. HER2 testing by local, central, and reference laboratories in the NCCTG N9831 Intergroup Adjuvant Trial. J Clin Oncol. 2004 Jul 15; 22: (14_suppl)567.
    View PubMed
  348. Ma CX, Steen P, Rowland KM, Niedringhaus RD, Kugler JW, Ingle JN, Perez EA, Adjei AA. A phase II study of a combination of pemetrexed (Pem) and gemcitabine (Gem) in patients with metastatic breast cancer (MBC): An NCCTG study. J Clin Oncol. 2004 Jul 15; 22: (14_suppl)639.
    View PubMed
  349. Miller DV, Leontovich AA, Lingle WL, Suman VJ, Mertens ML, Lillie J, Ingalls KA, Perez EA, Ingle JN, Couch FJ, Visscher DW. Utilizing Nottingham Prognostic Index in microarray gene expression profiling of breast carcinomas. Mod Pathol. 2004 Jul; 17(7):756-64.
    View PubMed
  350. Mincey BA, Perez EA. Advances in screening, diagnosis, and treatment of breast cancer. Mayo Clin Proc. 2004 Jun; 79(6):810-6.
    View PubMed
  351. Perez EA, Geoffroy FJ, Hillman S, Johnson EA, Farr GH Jr, Tazelarr HD, Hatfield AK, Krook JE, Maillard JA, Levitt R, Marks RS. Phase II study of oral etoposide and intravenous paclitaxel in extensive-stage small cell lung cancer. Lung Cancer. 2004 Jun; 44(3):347-53.
    View PubMed
  352. Perez EA, Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol. 2004 Jan 15; 22(2):322-9.
    View PubMed
  353. Perez EA. Gemcitabine and platinum combinations in patients with breast cancer previously treated with anthracyclines and/or taxanes. Clin Breast Cancer. 2004 Jan; 4 Suppl 3:S113-6
    View PubMed
  354. Perez EA, Robert NJ, Tripathy D. Trastuzumab in adjuvant therapy for breast cancer. The American Journal of Oncology Review. 2004; 3(6 Suppl 4):12-14.
  355. Perez EA. Carboplatin in combination therapy for metastatic breast cancer. Oncologist. 2004; 9(5):518-27.
    View PubMed
  356. Perez EA. Management recommendations for adjuvant systemic breast cancer therapy. Breast Dis. 2004; 21:15-21.
    View PubMed
  357. Perez E, Suman V, Davidson N, Kaufman P, Martino S, Dakhil S, Rodeheffer R, Gersh B, Jaffe A. Effect of Dozorubicin Plus Cyclophosphamide on Left Ventricular Ejection Fraction in Patients With Breast Cancer in the NCCTG N9831 Intergroup Adjuvant Trial J Clin Pathol. 2004; 22:3700-3704.
    View PubMed
  358. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003 Nov 6; 349(19):1793-802. Epub 2003 Oct 09.
    View PubMed
  359. Palmieri FM, Perez EA. Recent advances in adjuvant therapy for breast cancer. Semin Oncol Nurs. 2003 Nov; 19(4 Suppl 2):10-6.
    View PubMed
  360. Jatoi A, Stella PJ, Hillman S, Mailliard JA, Vanone S, Perez EA, Cannon MW, Geyer S, Wiesenfeld M, Jett JR. Weekly carboplatin and paclitaxel in elderly non-small-cell lung cancer patients (>or=65 years of age): a phase II North Central Cancer Treatment Group study. Am J Clin Oncol. 2003 Oct; 26(5):441-7.
    View PubMed
  361. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003 Apr 15; 21(8):1431-9. Epub 2003 Feb 13.
    View PubMed
  362. Formenti SC, Volm M, Skinner KA, Spicer D, Cohen D, Perez E, Bettini AC, Groshen S, Gee C, Florentine B, Press M, Danenberg P, Muggia F. Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and postoperative doxorubicin-based chemotherapy in locally advanced breast cancer: a phase I/II trial. J Clin Oncol. 2003 Mar 1; 21(5):864-70.
    View PubMed
  363. Perez EA, Gandara DR, Edelman MJ, O'Donnell R, Lauder IJ, DeGregorio M. Phase I trial of high-dose tamoxifen in combination with cisplatin in patients with lung cancer and other advanced malignancies. Cancer Invest. 2003; 21(1):1-6.
    View PubMed
  364. Perez E. Adjuvant chemotherapy: controversies and the role of taxanes. Breast J. 2003 Jan-Feb; 9 Suppl 1:S25-8.
    View PubMed
  365. Perez EA. Adjuvant therapy approaches to breast cancer: should taxanes be incorporated? Curr Oncol Rep. 2003 Jan; 5 (1):66-71
    View PubMed
  366. Perez E. Adjuvant chemotherapy: controversies and the tole of taxanes Breast J. 2003; 9 (Suppl 1):S25-8.
    View PubMed
  367. Chew B, Perez E. Traxtuzumab treatment for patients with HER2 positive breast cancer. Breast Cancer Online. 2003; 6(5):article = 180.
    View PubMed
  368. Loprinzi L, Barton DL, Sloan JA, Zahasky KM, Smith DA, Pruthi S, Novotny PJ, Perez EA, Christensen BJ. Pilot evaluation of gabapentin for treating hot flashes. Mayo Clin Proc. 2002 Nov; 77 (11):1159-63
    View PubMed
  369. Perez EA. Exploring newer chemotherapeutic and targeted biologic regimens for patients with advanced and metastatic breast cancer. Medscape CME Circle //wwwmedscapecom. 2002 Sep 20; URL:http.
  370. Perez EA, Geeraerts L, Suman VJ, Adjei AA, Baron AT, Hatfield AK, Maihle N, Michalak JC, Kuross SA, Kugler JW, Lafky JM, Ingle JN. A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer. Ann Oncol. 2002 Aug; 13: (8)1225-35.
    View PubMed
  371. Roche PC, Suman VJ, Jenkins RB, Davidson NE, Martino S, Kaufman PA, Addo FK, Murphy B, Ingle JN, Perez EA. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst. 2002 Jun 5; 94(11):855-7.
    View PubMed
  372. Qu G, Perez EA. Gemcitabine and targeted therapy in metastatic breast cancer. Semin Oncol. 2002 Jun; 29(3 Suppl 11):44-52.
    View PubMed
  373. Perez EA, Vogel CL, Irwin DH, Kirshner JJ, Patel R. Weekly paclitaxel in women age 65 and above with metastatic breast cancer. Breast Cancer Res Treat. 2002 May; 73(1):85-8.
    View PubMed
  374. Loprinzi CL, Sloan JA, Perez EA, Quella SK, Stella PJ, Mailliard JA, Halyard MY, Pruthi S, Novotny PJ, Rummans TA. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol. 2002 Mar 15; 20: (6)1578-83.
    View PubMed
  375. Perez EA. Anti-cancer treatment - 12th International Congress. 4-7 February 2002, Paris, France. IDrugs. 2002 Mar; 5(3):222-3.
    View PubMed
  376. Perez EA, Roche PC, Jenkins RB, Reynolds CA, Halling KC, Ingle JN, Wold LE. HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc. 2002 Feb; 77(2):148-54.
    View PubMed
  377. Maihle NJ, Lafky JM, Baron AT, Boardman CH, Greenwood TM, Christensen TA, Reiter JL, Cora EM, Lee H, Suman VJ, Fishman DA, Perez EA, Podratz KC. EGF receptor/ErbB isoforms as serum biomarkers in breast and ovarian cancer. Journal of Clinical Ligand Assay. 2002 Spr; 25(1):57-60.
    View PubMed
  378. Mincey BA, Vallow LA, Perez EA. Adjuvant therapy trials of radiotherapy and systemic treatment for breast cancer. Curr Oncol Rep. 2002 Jan; 4(1):1.
    View PubMed
  379. Mincey BA, Palmieri FM, Perez EA. Adjuvant therapy for breast cancer: recommendations for management based on consensus review and recent clinical trials. Oncologist. 2002; 7(3):246-50.
    View PubMed
  380. Kuriakose P, Gandara DR, Perez EA. Phase I trial of edatrexate in advanced breast and other cancers. Cancer Invest. 2002; 20(4):473-9.
    View PubMed
  381. Roche P, Suman V, Jenkins R, Davidson N, Martino S, Kaufman P, Addo F, Murphy B, Ingle J, Perez E. Determination of HER-2 Status for the Breast Intergroup Trial N9831: Concordance Between Local and Central Laboratory Testing and the Correlation of Overexpression and Amplification Journal of the National Cancer Institute. 2002; 94:855-857.
    View PubMed
  382. Perez EA, Vogel CL, Irwin DH, Kirshner JJ, Patel R. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol. 2001 Nov 15; 19: (22)4216-23.
    View PubMed
  383. Perez EA. The role of adjuvant monoclonal antibody therapy for breast cancer: rationale and new studies. Curr Oncol Rep. 2001 Nov; 3 (6):516-22
    View PubMed
  384. Baron AT, Lafky JM, Suman VJ, Hillman DW, Buenafe MC, Boardman CH, Podratz KC, Perez EA, Maihle NJ. A preliminary study of serum concentrations of soluble epidermal growth factor receptor (sErbB1), gonadotropins, and steroid hormones in healthy men and women. Cancer Epidemiol Biomarkers Prev. 2001 Nov; 10(11):1175-85.
    View PubMed
  385. Hortobagyi GN, Perez EA. Integration of trastuzumab into adjuvant systemic therapy of breast cancer: ongoing and planned clinical trials. Semin Oncol. 2001 Oct; 28(5 Suppl 16):41-6.
    View PubMed
  386. Perez EA. Adjuvant anti-HER2 monoclonal antibody therapy - ready for breast cancer? Breast. 2001 Aug; 10(Suppl 3):161-163.
  387. Valero V, Perez E, Dieras V. Doxorubicin and taxane combination regimens for metastatic breast cancer: focus on cardiac effects. Semin Oncol. 2001 Aug; 28(4 Suppl 12):15-23.
    View PubMed
  388. Perez EA. Metastatic bone disease in breast cancer: the patient's perspective. Semin Oncol. 2001 Aug; 28(4 Suppl 11):60-3.
    View PubMed
  389. Mincey BA, Bammer T, Atkinson EJ, Perez EA. Role of axillary node dissection in patients with T1a and T1b breast cancer: Mayo Clinic experience. Arch Surg. 2001 Jul; 136(7):779-82.
    View PubMed
  390. Lara PN Jr, Gandara DR, Longmate J, Gumerlock PH, Lau DH, Edelman MJ, Gandour-Edwards R, Mack PC, Israel V, Raschko J, Frankel P, Perez EA, Lenz HJ, Doroshow JH. Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium Trial. Cancer Chemother Pharmacol. 2001 Jul; 48(1):22-8.
    View PubMed
  391. Perez EA. Doxorubicin and paclitaxel in the treatment of advanced breast cancer: efficacy and cardiac considerations. Cancer Invest. 2001; 19(2):155-64.
    View PubMed
  392. Perez EA, Romond E. Trastuzumab (Herceptin®) in adjuvant therapy of breast cancer: a summary of current and proposed trials. Biological Therapy of Breast Cancer. 2001; 2(4):2-5.
  393. Perez EA. Incorporation of taxanes in the adjuvant management of patients with breast cancer, incorporating data presented at the 2000 NIH Consensus Development Conference. Advances in Breast Cancer. 2001; 3(2):2-5.
  394. Perez EA, Hortobagyi GN. Ongoing and planned adjuvant trials with trastuzumab. Semin Oncol. 2000 Dec; 27(6 Suppl 11):26-32; discussion 92-100.
    View PubMed
  395. Rhodes DJ, Hartmann LC, Perez EA. Breast cancer prevention trials. Curr Oncol Rep. 2000 Nov; 2 (6):558-65
    View PubMed
  396. Perez EA. Rationale and design of a phase III trial of adjuvant sequential epirubicin/ cyclophosphamide and taxane versus concurrent epirubicin/taxane in operable node-positive breast cancer. Clin Breast Cancer. 2000 Sep; 1 Suppl 1:S52-6
    View PubMed
  397. Mincey BA, Moraghan TJ, Perez EA. Prevention and treatment of osteoporosis in women with breast cancer. Mayo Clin Proc. 2000 Aug; 75(8):821-9.
    View PubMed
  398. Loprinzi CL, Alberts SR, Christensen BJ, Hanson LJ, Farley DR, Broers JK, Betcher DL, Grady RE, Southorn PA, Johnson TM, Perez EA. History of the development of antiemetic guidelines at Mayo Clinic Rochester. Mayo Clin Proc. 2000 Mar; 75(3):303-9.
    View PubMed
  399. Bonner JA, Sloan JA, Rowland KM Jr, Klee GG, Kugler JW, Mailliard JA, Wiesenfeld M, Krook JE, Maksymiuk AW, Shaw EG, Marks RS, Perez EA. Significance of neuron-specific enolase levels before and during therapy for small cell lung cancer. Clin Cancer Res. 2000 Feb; 6(2):597-601.
    View PubMed
  400. Perez EA, Hillman DW, Stella PJ, Krook JE, Hartmann LC, Fitch TR, Hatfield AK, Mailliard JA, Nair S, Kardinal CG, Ingle JN. A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma. Cancer. 2000 Jan 1; 88(1):124-31.
    View PubMed
  401. Hesketh PJ, Roman A, Hesketh AM, Perez EA, Edelman M, Gandara DR. Control of high-dose-cisplatin-induced emesis with an all-oral three-drug antiemetic regimen. Support Care Cancer. 2000 Jan; 8(1):46-8.
    View PubMed
  402. Perez EA, Tiemeier T, Solberg LA. Antiemetic therapy for high-dose chemotherapy with transplantation: report of a retrospective analysis of a 5-HT(3) regimen and literature review. Support Care Cancer. 1999 Nov; 7(6):413-24.
    View PubMed
  403. Perez EA. 5-HT3 antiemetic therapy for patients with breast cancer. Breast Cancer Res Treat. 1999 Sep; 57(2):207-14.
    View PubMed
  404. Perez EA. Update on metastatic breast cancer. Curr Oncol Rep. 1999 Sep; 1 (1):11-5
    View PubMed
  405. Perez EA. Current management of metastatic breast cancer. Semin Oncol. 1999 Aug; 26(4 Suppl 12):1-10.
    View PubMed
  406. Quella SK, Loprinzi CL, Sloan J, Novotny P, Perez EA, Burch PA, Antolak SJ Jr, Pisansky TM. Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer. J Urol. 1999 Jul; 162(1):98-102.
    View PubMed
  407. Ingle JN, Suman VJ, Johnson PA, Krook JE, Mailliard JA, Wheeler RH, Loprinzi CL, Perez EA, Jordan VC, Dowsett M. Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer. Clin Cancer Res. 1999 Jul; 5(7):1642-9.
    View PubMed
  408. Perez EA. Paclitaxel plus nonanthracycline combinations in metastatic breast cancer. Semin Oncol. 1999 Feb; 26(1 Suppl 2):21-6.
    View PubMed
  409. Perez EA. HER-2 as a prognostic, predictive, and therapeutic target in breast cancer. Cancer Control. 1999; 6(3):233-40.
    View PubMed
  410. Perez EA. State of the art management of locally advanced breast cancer. Cancer Research, Therapy & Control. 1999; 9(3-4):261-6.
  411. Perez EA. State of the art therapy for metastatic breast cancer. Cancer Research, Therapy & Control. 1999; 9(3-4):289-95.
  412. Perez EA, Horton J, Muss HB. Management of bone metastases in advanced breast cancer. Cancer Control. 1999; 6(5 Suppl):28-31.
    View PubMed
  413. Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW, Clark-Snow R, Gill DP, Groshen S, Grunberg S, Koeller JM, Morrow GR, Perez EA, Silber JH, Pfister DG. Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines. J Clin Oncol. 1999; 17(9):2971-94.
    View PubMed
  414. Denardo SJ, Richman CM, Kukis DL, Shen S, Lamborn KR, Miers LA, Kroger LA, Perez EA, Denardo GL. Synergistic therapy of breast cancer with Y-90-chimeric L6 and paclitaxel in the xenografted mouse model: development of a clinical protocol. Anticancer Res. 1998 Nov-Dec; 18(6A):4011-8.
    View PubMed
  415. Perez EA. Perceptions of prognosis, treatment, and treatment impact on prognosis in non-small cell lung cancer. Chest. 1998 Aug; 114(2):593-604.
    View PubMed
  416. Loprinzi CL, Pisansky TM, Fonseca R, Sloan JA, Zahasky KM, Quella SK, Novotny PJ, Rummans TA, Dumesic DA, Perez EA. Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol. 1998 Jul; 16: (7)2377-81.
    View PubMed
  417. Gandara DR, Roila F, Warr D, Edelman MJ, Perez EA, Gralla RJ. Consensus proposal for 5HT(3) antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy - dose, schedule, and route of administration. Support Care Cancer. 1998 May; 6(3):237-43.
    View PubMed
  418. Perez EA. Use of dexamethasone with 5-HT3-receptor antagonists for chemotherapy-induced nausea and vomiting. Cancer J Sci Am. 1998 Mar-Apr; 4(2):72-7.
    View PubMed
  419. Perez EA, Hesketh P, Sandbach J, Reeves J, Chawla S, Markman M, Hainsworth J, Bushnell W, Friedman C. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. J Clin Oncol. 1998 Feb; 16: (2)754-60.
    View PubMed
  420. Perez EA. A risk-benefit assessment of serotonin 5-HT3 receptor antagonists in antineoplastic therapy-induced emesis. Drug Saf. 1998 Jan; 18 (1):43-56
    View PubMed
  421. Perez EA, Lembersky B, Kaywin P, Kalman L, Yocom K, Friedman C. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy. Cancer J Sci Am. 1998 Jan-Feb; 4(1):52-8.
    View PubMed
  422. Perez EA, Buckwalter CA. Sequence-dependent cytotoxicity of etoposide and paclitaxel in human breast and lung cancer cell lines. Cancer Chemother Pharmacol. 1998; 41(6):448-52.
    View PubMed
  423. Edelman MJ, Gandara DR, Perez EA, Lau D, Lauder I, Turrell C, Uhrich M, Meyers F. Phase I trial of edatrexate plus carboplatin in advanced solid tumors: amelioration of dose-limiting mucositis by ice chip cryotherapy. Invest New Drugs. 1998; 16(1):69-75.
    View PubMed
  424. Lara PN Jr, Gandara DR, Wurz GT, Lau D, Uhrich M, Turrell C, Raschko J, Edelman MJ, Synold T, Doroshow J, Muggia F, Perez EA, DeGregorio M. High-dose toremifene as a cisplatin modulator in metastatic non-small cell lung cancer: targeted plasma levels are achievable clinically. Cancer Chemother Pharmacol. 1998; 42(6):504-8.
    View PubMed
  425. Perez EA. Paclitaxel in breast cancer. Oncologist. 1998; 3(6):373-89.
    View PubMed
  426. Perez EA. Preclinical pharmacology and comparative efficacy of 5-hydroxytryptamine-3 receptor antagonists for acute chemotherapy-induced emesis: A short review. Topics in Supp Care Oncol. 1998; 27:8-10.
  427. Perez EA. Appropriate use of 5-HT3-receptor antiemetics. Health Care Innov Special Supplement: Maximizing Antiemetic Outcomes in a Managed Care Environment. 1997 Nov/Dec.
  428. Perez EA, Foo ML, Fulmer JT. Management of locally advanced breast cancer. Oncology (Williston Park). 1997 Sep; 11: (9 Suppl 9)9-17.
    View PubMed
  429. Perez EA, Loprinzi CL, Sloan JA, Owens DT, Novotny PJ, Bonner JA. Utility of screening procedures for detecting recurrence of disease after complete response in patients with small cell lung carcinoma. Cancer. 1997 Aug 15; 80(4):676-80.
    View PubMed
  430. Perez EA, Navari RM, Kaplan HG, Gralla RJ, Grunberg SM, Palmer RH, Fitts D. Efficacy and safety of different doses of granisetron for the prophylaxis of cisplatin-induced emesis. Support Care Cancer. 1997 Jan; 5 (1):31-7
    View PubMed
  431. Gandara DR, Crowley J, Livingston RB, Perez EA, et al. Evaluation of cisplatin intensity in metastatic non-small cell lung cancer: a phase III study of the Southwest Oncology Group. Classic Papers and Current Comments. 1997; 2(1):178-84.
  432. Perez EA, Buckwalter CA, Reid JP. Combinations of paclitaxel and etoposide in the treatment of lung cancer. Semin Oncol. 1996 Dec; 23(6 Suppl 15):21-5.
    View PubMed
  433. Perez EA, Hartmann LC. Paclitaxel and carboplatin for advanced breast cancer. Semin Oncol. 1996 Oct; 23(5 Suppl 11):41-5.
    View PubMed
  434. Perez EA. Comparative efficacy of oral and intravenous granisetron for the prevention of acute chemotherapy-induced emesis. Clin Ther. 1996 Jul-Aug; 18(4):578-90; discussion 577.
    View PubMed
  435. Hesketh PJ, Gandara DR, Hesketh AM, Facada A, Perez EA, Webber LM, Martin LA, Cramer MB, Hahne WF. Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide. Support Care Cancer. 1996 Mar; 4(2):141-6.
    View PubMed
  436. Perez EA. Managing chemotherapy-induced nausea and vomiting. P T. 1996; 21(3 Suppl):5s-14s.
  437. Perez EA, Coe T, Turrell C, Campbell D, Lau D, Gandara DR. Phase I study of paclitaxel and oral etoposide in advanced tumors. Cancer J Sci Am. 1996; 2:286-90.
    View PubMed
  438. Perez EA. Overview: oral granisetron (Kytril tablets) prophylaxis for chemotherapy-induced nausea and vomiting. Semin Oncol. 1995 Aug; 22(4 Suppl 10):1-2.
    View PubMed
  439. Perez EA. Review of the preclinical pharmacology and comparative efficacy of 5-hydroxytryptamine-3 receptor antagonists for chemotherapy-induced emesis. J Clin Oncol. 1995 Apr; 13(4):1036-43.
    View PubMed
  440. Perez EA, Campbell DL, Ryu JK. Radiation recall dermatitis induced by edatrexate in a patient with breast cancer. Cancer Invest. 1995; 13(6):604-7.
    View PubMed
  441. Gandara DR, Hahhas WA, Adelson MD, Lichtman SM, Podczaski ES, Yanovich S, Homesley HD, Braly P, Ritch PS, Weisberg SR, Perez EA. Randomized placebo-controlled multicenter evaluation of diethyldithiocarbamate for chemoprotection against cisplatin-induced toxicities. J Clin Oncol. 1995; 13(2):490-6.
    View PubMed
  442. Perez EA, Gandara DR. The clinical role of granisetron (Kytril) in the prevention of chemotherapy-induced emesis. Semin Oncol. 1994 Jun; 21(3 Suppl 5):15-21.
    View PubMed
  443. Perez EA, Gandara DR. Etoposide/ifosfamide/cisplatin regimens in metastatic non-small cell lung cancer. Semin Oncol. 1994 Jun; 21(3 Suppl 4):2-5.
    View PubMed
  444. Perez EA, Hack FM, Fletcher TS, Chou TC. Modulation of intrinsic in vitro resistance to carboplatin by edatrexate in the A549 human nonsmall cell lung cancer cell line. Oncol Res. 1994; 6(3):151-6.
    View PubMed
  445. Costa MJ, Stewart G, Perez EA, Goodnight JE. Fine-needle aspiration cytology in locally advanced breast adenocarcinoma: a case with complete response to preoperative chemotherapy in association with granulomatous inflammatory reaction. Diagn Cytopathol. 1994; 10(4):357-61.
    View PubMed
  446. Perez EA, Sowray PC, Gardner SL, Gandara DR. Phase I study of high-dose cisplatin, ifosfamide, and etoposide. Cancer Chemother Pharmacol. 1994; 34(4):331-4.
    View PubMed
  447. Perez EA. Clinical comparative efficacy and safety of 5-HT3 antagonists for chemotherapy induced emesis. Hosp Formul. 1994; 29(S5):S18-23.
  448. Gandara DR, Crowley J, Livingston RB, Perez EA, Taylor CW, Weiss G, Neefe JR, Hutchins LF, Roach RW, Grunberg SM. Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group. J Clin Oncol. 1993 May; 11(5):873-8.
    View PubMed
  449. Perez EA, Hack FM, Webber LM, Chou TC. Schedule-dependent synergism of edatrexate and cisplatin in combination in the A549 lung-cancer cell line as assessed by median-effect analysis. Cancer Chemother Pharmacol. 1993; 33(3):245-50.
    View PubMed
  450. Valone FH, Gandara DR, Luce JA, Wall S, Perez EA, Braham N, George M, Letvak L. Phase I trial of a 5-day infusion of L-leucovorin plus daily bolus 5-fluorouracil in patients with advanced gastrointestinal malignancies. Cancer Chemother Pharmacol. 1993; 32(3):215-20.
    View PubMed
  451. Gandara DR, Harvey WH, Monaghan GG, Perez EA, Hesketh PJ. Delayed emesis following high-dose cisplatin: a double-blind randomised comparative trial of ondansetron (GR 38032F) versus placebo. Eur J Cancer. 1993; 29A Suppl 1:S35-8.
    View PubMed
  452. Perez EA, Gandara DR. Advances in the control of chemotherapy-induced emesis. Ann Oncol. 1992 Aug; 3 Suppl 3:47-50.
    View PubMed
  453. Gandara DR, Harvey WH, Monaghan GG, Perez EA, Stokes C, Bryson JC, Finn AL, Hesketh PJ. The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo. Semin Oncol. 1992 Aug; 19(4 Suppl 10):67-71.
    View PubMed
  454. Perez EA, Hallstone AE. Chemotherapy-induced emesis: prevention and management. Contemp Oncol. 1992; 10:34-43.
  455. Valone FH, Gandara DR, Deisseroth AB, Perez EA, Rayner A, Aronson FR, Luce J, Paradise C. Interleukin-2, cisplatin, and 5-fluorouracil for patients with non-small cell lung and head/neck carcinomas. J Immunother. 1991 Jun; 10(3):207-13.
    View PubMed
  456. Gandara DR, Valone FH, Perez EA, Deisseroth AB, Roach M 3rd, Ahn DK, Phillips T. Rapidly alternating radiotherapy and high dose cisplatin chemotherapy in stage IIIB non-small cell lung cancer: results of a phase I/II study. Int J Radiat Oncol Biol Phys. 1991 May; 20(5):1047-52.
    View PubMed
  457. Perez EA, Scudder SA, Meyers FA, Tanaka MS, Paradise C, Gandara DR. Weekly 24-hour continuous infusion interleukin-2 for metastatic melanoma and renal cell carcinoma: a phase I study. J Immunother. 1991 Feb; 10(1):57-62.
    View PubMed
  458. Perez EA, Hesketh PJ, Gandara DR. Serotonin antagonists in the management of cisplatin-induced emesis. Semin Oncol. 1991 Feb; 18(1 Suppl 3):73-80.
    View PubMed
  459. Gandara DR, Perez EA, Weibe V, De Gregorio MW. Cisplatin chemoprotection and rescue: pharmacologic modulation of toxicity. Semin Oncol. 1991 Feb; 18(1 Suppl 3):49-55.
    View PubMed
  460. Gandara DR, Wiebe VJ, Perez EA, Makuch RW, DeGregorio MW. Cisplatin rescue therapy: experience with sodium thiosulfate, WR2721, and diethyldithiocarbamate. Crit Rev Oncol Hematol. 1990; 10(4):353-65.
    View PubMed
  461. Gandara DR, Perez EA, Wold H, Caggiano V, Malec M, Ahn DK, Meyers F, Carlson RW. High-dose cisplatin and mitomycin C in advanced non-small cell lung cancer: a phase II study of the Northern California Oncology Group. Cancer Chemother Pharmacol. 1990; 27(3):243-7.
    View PubMed
  462. Stanton TS, Perez EA, Gandara DR. Chemotherapy of metastatic testicular cancer: current status and future prospects. World J Urol. 1990; 8:20-6.
  463. Gandara DR, Perez EA, Phillips WA, Lawrence HJ, DeGregorio M. Evaluation of cisplatin dose intensity: current status and future prospects. Anticancer Res. 1989 Jul-Aug; 9(4):1121-8.
    View PubMed
  464. Gandara DR, Wold H, Perez EA, Deisseroth AB, Doroshow J, Meyers F, McWhirter K, Hannigan J, De Gregorio MW. Cisplatin dose intensity in non-small cell lung cancer: phase II results of a day 1 and day 8 high-dose regimen. J Natl Cancer Inst. 1989 May 10; 81(10):790-4.
    View PubMed
  465. Gandara DR, Perez EA, Denham A, Wiebe VJ, DeGregorio MW. Pharmacokinetics of cisplatin in patients receiving interleukin-2-containing treatment regimens. Cancer Chemother Pharmacol. 1989; 24(2):135-6.
    View PubMed
  466. DeGregorio MW, Gandara DR, Holleran WM, Perez EA, King CC, Wold HG, Montine TJ, Borch RF. High-dose cisplatin with diethyldithiocarbamate (DDTC) rescue therapy: preliminary pharmacologic observations. Cancer Chemother Pharmacol. 1989; 23(5):276-8.
    View PubMed
  467. Hutchison FN, Perez EA, Gandara DR, Lawrence HJ, Kaysen GA. Renal salt wasting in patients treated with cisplatin. Ann Intern Med. 1988 Jan; 108(1):21-5.
    View PubMed